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Obesity is an increasingly prevalent disease regulated by genetic and environmental factors. Emerging
studies indicate that immune cells, including monocytes, granulocytes and lymphocytes, regulate
metabolic homeostasis and are dysregulated in obesity. Group 2 innate lymphoid cells (ILC2s) can
regulate adaptive immunity and eosinophil and alternatively-activated macrophage responses, and were
recently identified in murine white adipose tissue (WAT) where they may act to limit the development of
obesity. However, ILC2s have not been identified in human adipose tissue, and the mechanisms by which
ILC2s regulate metabolic homeostasis remain unknown. Here, we identify ILC2s in human WAT and
demonstrate that decreased ILC2 responses in WAT are a conserved characteristic of obesity in humans
and mice. Interleukin (IL)-33 was found to be critical for the maintenance of ILC2s in WAT and in limiting
adiposity in mice by increasing caloric expenditure. This was associated with recruitment of uncoupling
protein 1 (UCP1)+ beige adipocytes in WAT, a process known as beiging or browning that regulates
caloric expenditure. IL-33-induced beiging was dependent on ILC2s, and IL-33 treatment or transfer of
IL-33-elicited ILC2s was sufficient to drive beiging independently of the adaptive immune system,
eosinophils or IL-4 receptor signaling. We found that ILC2s produce methionine-enkephalin peptides that
can act directly on adipocytes to upregulate Ucp1 expression in vitro and that promote beiging in vivo.
Collectively, these studies indicate that in addition to responding to infection or tissue damage, ILC2s can
regulate adipose function and metabolic homeostasis in part via production of enkephalin peptides that
elicit beiging.
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ABSTRACT
INNATE IMMUNE CELL REGULATION OF METABOLIC HOMEOSTASIS
Jonathan R. Brestoff
David Artis

Obesity is an increasingly prevalent disease regulated by genetic and
environmental factors. Emerging studies indicate that immune cells, including
monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and
are dysregulated in obesity. Group 2 innate lymphoid cells (ILC2s) can regulate
adaptive immunity and eosinophil and alternatively-activated macrophage
responses, and were recently identified in murine white adipose tissue (WAT)
where they may act to limit the development of obesity. However, ILC2s have
not been identified in human adipose tissue, and the mechanisms by which
ILC2s regulate metabolic homeostasis remain unknown. Here, we identify ILC2s
in human WAT and demonstrate that decreased ILC2 responses in WAT are a
conserved characteristic of obesity in humans and mice. Interleukin (IL)-33 was
found to be critical for the maintenance of ILC2s in WAT and in limiting adiposity
in mice by increasing caloric expenditure. This was associated with recruitment
of uncoupling protein 1 (UCP1)+ beige adipocytes in WAT, a process known as
beiging or browning that regulates caloric expenditure. IL-33-induced beiging
was dependent on ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s
was sufficient to drive beiging independently of the adaptive immune system,
eosinophils or IL-4 receptor signaling. We found that ILC2s produce methionineenkephalin peptides that can act directly on adipocytes to upregulate Ucp1
v

expression in vitro and that promote beiging in vivo. Collectively, these studies
indicate that in addition to responding to infection or tissue damage, ILC2s can
regulate adipose function and metabolic homeostasis in part via production of
enkephalin peptides that elicit beiging.
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Chapter 1: Immune cell regulation of metabolic
homeostasis

1.1 Obesity is a global public health problem regulated by genetic
and environmental factors
Obesity is in an increasingly prevalent metabolic disease characterized by
excess accumulation of adipose tissue. Obesity increases the risk of developing
a wide variety of diseases including type 2 diabetes, cardiovascular diseases and
multiple forms of cancer, and has been strongly associated with increased
mortality(Collaboration, 2009; Flegal et al., 2013; Oliveros and Villamor, 2008; PiSunyer, 1999; Pontiroli and Morabito, 2011; Reilly and Kelly, 2011; Rodriguez et
al., 2001).

In the past few decades, the prevalence of obesity has risen

dramatically in both developed and developing nations across all continents
(Kelly et al., 2008; Ng et al., 2014), and this has been associated with high
1

healthcare expenditures (Withrow and Alter, 2011). For example, in the United
States, where the prevalence of obesity among adults was 36% in 2010 (Flegal
et al., 2012; Ogden et al., 2012, 2014), obesity accounts for approximately $190
billion annually or 20% of total national health care expenditures (Cawley and
Meyerhoefer, 2012; Finkelstein et al., 2009).

Therefore, obesity is a critical

problem with major health and economic consequences.

Increasing our

understanding of the pathways involved in the development of obesity will be
critical for the development of new intervention strategies to prevent or treat this
disease and its associated comorbidities.

Genetic and environmental factors are important for the development of obesity
and associated diseases (Bouchard, 2008; Brestoff and Artis, 2013; McCarthy,
2010; Walley et al., 2009). In addition, emerging studies have implicated various
cell types in the immune system as critical regulators of metabolic homeostasis
(Jin et al., 2013; Lumeng and Saltiel, 2011; Odegaard and Chawla, 2011, 2013b;
Osborn and Olefsky, 2012). In white adipose tissue (WAT), which regulates
metabolism at distant tissues such as the brain, liver and muscle, there is a
diverse set of immune cells at steady state (Exley et al., 2014; Ibrahim, 2010;
McNelis and Olefsky, 2014; Mraz and Haluzik, 2014). This network of immune
cells appears to be poised to recognize, integrate and respond to environmental
signals including bacterial products, endogenous lipid species and hormones in
order to coordinate metabolism (Odegaard and Chawla, 2013a). Changes in
2

immune cell composition and function in WAT have been closely associated with
obesity and the regulation of metabolic homeostasis, and disruption of this
network of immune cells can have either detrimental or beneficial effects on
mammalian health (Exley et al., 2014; Lumeng and Saltiel, 2011; Mraz and
Haluzik, 2014; Odegaard and Chawla, 2013b; Osborn and Olefsky, 2012). This
implies that dissecting the complex interactions between immune and metabolic
systems will be important for understanding the biology underlying obesity and
have implications for understanding how current and future therapeutics might
influence metabolism.

The purpose of this Chapter is to describe our current understanding of how
immune cells in white adipose tissue regulate metabolism.

First, we will

summarize recent advances in the roles of white, beige and brown adipose
tissues in the regulation of weight gain. Second, we will describe the immune
cell composition of adipose tissue at steady state and discuss how these immune
cell pathways interact and contribute to the maintenance of metabolic
homeostasis. Third, we will characterize immunologic changes that occur in
adipose in the setting of obesity and discuss how these changes contribute to
metabolic dysfunction. Finally, we will discuss potential therapeutic implications
of targeting the immune system to treat obesity and its associated diseases.

3

1.2 Roles of adipose tissues in the regulation of obesity
Mammals possess multiple types of adipose tissues including white, brown and
beige adipose. These tissues are found in distinct anatomic locations and are
comprised of different adipocyte cell types – white, beige and/or brown – that
have unique developmental and functional properties that are critical for host
metabolism (Fig. 1) (Bartelt and Heeren, 2014; Cannon and Nedergaard, 2004;
Harms and Seale, 2013; Ibrahim, 2010; Peirce et al., 2014; Pfeifer and
Hoffmann, 2014; Wu et al., 2013).

This section describes white, brown and

beige adipocyte cell types and summarizes their roles in regulating weight gain.

1.2.1 White adipocytes
White adipose tissue (WAT) is distributed in subcutaneous depots and in
association with organs, where it has important roles in insulation and physical
protection of the viscera, and is comprised predominantly of white adipocytes
(Peirce et al., 2014; Pfeifer and Hoffmann, 2014). These specialized cell types
arise from a Myf5− pre-adipocyte lineage and store large amounts of triglycerides
in a single large lipid droplet (Pfeifer and Hoffmann, 2014; Sanchez-Gurmaches
and Guertin, 2014).

In addition to their ability to store triglycerides, white

adipocytes respond to hormonal signals to induce lipolysis and release free fatty
acids (FFA) into the circulation for oxidation or storage by other cell types (Arner
et al., 2011; Bartness et al., 2010). Therefore, white adipocytes are critical for
regulating both fat storage and release. Beyond this function, white adipocytes
4

produce various adipocyte-specific hormones (also known as adipokines) such
as leptin, resistin, retinol binding protein 4 (RBP4) and adiponectin among other
adipokines that regulate metabolic homeostasis by acting on distant organs such
as the brain, kidney, liver and skeletal muscle (Allison and Myers, 2014;
Kadowaki et al., 2006; Kershaw and Flier, 2004; Kotnik et al., 2011; Lazar, 2007;
Ouchi et al., 2011).

In the context of obesity, mature white adipocytes become hypertrophic through
accumulation of triglycerides (Kubota et al., 1999), and adipocytes proliferate to
increase adipocyte numbers in WAT (Foster and Bartness, 2006; Hausman et
al., 2001; Spalding et al., 2008).

As WAT expands, adipocytes increase

production of leptin to suppress food intake and therefore limit the rate of
triglyceride accumulation and adipocyte expansion (Allison and Myers, 2014).
Leptin also has pro-inflammatory effects by eliciting type 1 effector cytokine
production by immune cells (Attie and Scherer, 2009; Gregor and Hotamisligil,
2011; Mraz and Haluzik, 2014; Ouchi et al., 2011). In addition to leptin, RBP4
and resistin production by white adipocytes are increased in obesity, and both of
these factors promote insulin resistance in mice (Kotnik et al., 2011; Lazar, 2007;
Moraes-Vieira et al., 2014; Norseen et al., 2012; Steppan et al., 2001; Yang et
al., 2005). Upregulation of RBP4 expression has been linked to inappropriate
sensing of low glucose levels by adipocytes (Yang et al., 2005), whereas resistin
levels are regulated by insulin and TNF-α among other factors (Lazar, 2007;
5

Song et al., 2002). Both of these factors appear to promote insulin resistance in
mice, at least in part, through elicitation of a type 1 immune responses in WAT
(Jung and Choi, 2014; Ouchi et al., 2011). In contrast to leptin, resistin and
RBP4, adiponectin production by white adipocytes is decreased in the context of
obesity (Ouchi et al., 2011). In addition, adiponectin has insulin-sensitizing and
anti-inflammatory effects (Gregor and Hotamisligil, 2011; Kadowaki et al., 2006;
Lumeng and Saltiel, 2011), and loss of this anti-inflammatory signal may be one
factor that contributes to the development of inflammation in WAT in obesity.
Therefore white adipocytes appear to link metabolic status of mammals to
immune responses in WAT.

1.2.2 Brown adipocytes
Although brown adipocytes can also produce adipokines, these cells differ from
white adipocytes developmentally, functionally and anatomically. In mice, brown
adipocytes arise from a Myf5+ lineage and are developmentally more closely
related to skeletal muscle cells than to white adipocytes (Kajimura et al., 2009;
Seale et al., 2008). The primary function of brown adipocytes in both mice and
humans is to convert chemical energy into heat via Uncoupling protein 1 (UCP1)
(Cannon and Nedergaard, 2004).

UCP1 is a long chain fatty acid/proton

symporter that dissipates the mitochondrial electrochemical gradient, thereby
uncoupling energy substrate oxidation from ATP synthesis and resulting in the
generation of heat (Fedorenko et al., 2012; Matthias et al., 2000). This process
6

is critical for maintaining core body and in the regulation of weight gain by
regulating whole body energy expenditure. In the latter case, for example, mice
that lack UCP1 develop obesity when housed at thermoneutrality (30°C) as
compared to UCP1-sufficient controls (Feldmann et al., 2009). Although global
deletion of UCP1 impairs thermogenesis in both brown and beige adipocytes,
interscapular BAT is believed to be an important regulator of metabolic rate and
obesity susceptibility in mice.

Brown adipocytes are found in discrete brown adipose tissue (BAT) depots. In
mice, the largest BAT depot is present in the interscapular space and smaller
depots are present in the axilla and along the cervical column (Bartelt and
Heeren, 2014). In humans, brown adipocytes are abundant in newborns
including the interscapular space (Hondares et al., 2014), whereas in lean adult
humans brown adipocytes are reported to be present in the supraclavicular
space of the neck and adjacent to the cervical column and heart (van Marken
Lichtenbelt et al., 2009; Virtanen et al., 2009).

Subsequent studies have

determined that in healthy adults supraclavicular neck BAT exhibits a gene
expression profile and has morphologic characteristics consistent with beige
adipocytes (Lee et al., 2014; Sharp et al., 2012; Wu et al., 2012).

7

1.3.3 Beige adipocytes
Like brown adipocytes, beige adipocytes (also known as brown-like or brite
adipocytes) express high levels of UCP1 and store triglyceride in one or more
lipid droplets, giving rise to a paucilocular or multilocular cell morphology.
However, beige and brown adipocytes differ from each other in their
developmental and anatomic characteristics.

Brown adipocytes arise from a

Myf5+ precursor and are developmentally related to skeletal muscle cells
(Kajimura et al., 2009; Seale et al., 2008), whereas beige adipocytes arise from
Myf5− precursors within WAT and are developmentally related to smooth muscle
cells (Long et al., 2014) and/or white adipocytes (Sanchez-Gurmaches and
Guertin, 2014).

Beige adipocytes are believed to arise from multiple

developmental pathways, including differentiation from committed beige preadipocytes as well as white-to-beige transdifferentiation in which mature white
adipocytes are converted into a beige adipocyte (Fig. 1) (Barbatelli et al., 2010;
Harms and Seale, 2013; Moisan et al., 2014; Sanchez-Gurmaches and Guertin,
2014; Wang et al., 2013b; Wu et al., 2012). This suggests that there is a close
developmental relationship between white and beige adipocytes and that there
may be distinct developmental pathways resulting in a heterogeneous population
of beige adipocytes. In mice, beige adipocytes are enriched in subcutaneous
WAT compared to visceral fat, however beige adipocytes are elicited in both
subcutaneous and visceral WAT (Qiu et al., 2014). Whether beige adipocytes in
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subcutaneous and visceral fat differ from each other developmentally or
functionally remains unclear.

Beige adipocytes are elicited in response to environmental stimuli including
exposure to cold environmental temperatures and are activated or induced to
differentiate in response to a range of small molecules and hormones, including
norepinephrine (Qiu et al., 2014; Rao et al., 2014), adenosine (Gnad et al.,
2014), lactate (Carriere et al., 2014), β-aminoisobutyric acid (BAIBA) (Roberts et
al., 2014), prostaglandin E2 (PGE2) (Madsen et al., 2010), parathyroid hormonerelated protein (PTHrp) (Fisher et al., 2012), bone morphogenetic protein 4
(BMP4) (Qian et al., 2013), BMP7 (Schulz et al., 2011), fibroblast growth factor
21 (FGF21) (Fisher et al., 2012), irisin (Wu et al., 2012) and meteorin-like (Rao et
al., 2014).

Although many factors are known to promote beige adipocyte

differentiation or function, it remains unknown whether these factors act on
different subsets of beige adipocytes or whether they elicit developmentally or
functionally distinct subsets of beige adipocytes. In addition, it is unclear whether
these factors coordinately regulate beige adipocyte function.

Nonetheless, recent studies indicate that selective deletion of beige but not
brown adipocytes results in impaired glucose homeostasis and increased
susceptibility to weight gain in response to high fat diet feeding (Cohen et al.,
9

2014).

Conversely, deletion of LGR4 results in enhanced beige adipocyte

development and function and is associated with increased metabolic rate and
decreased obesity (Wang et al., 2013a). Further, 129Sv mice that are resistant
to diet-induced obesity exhibit increased beiging of WAT compared to C57BL/6
mice that are susceptible to diet-induced obesity (Shabalina et al., 2013).
Feeding 129Sv mice a HFD supplemented with indomethacin blunted the
PGE2/beige adipocyte pathway and resulted in increased accumulation of WAT
compared to controls fed a HFD without indomethacin (Madsen et al., 2010). In
the context of human obesity, the incidence of brown/beige adipose tissue
(Sharp et al., 2012) is significantly decreased in obese patients compared to lean
patients (Saito et al., 2009), and ephedrine-induced activation of this tissue is
impaired in human obesity (Carey et al., 2013). In addition, UCP1 expression
was found to be higher in cultured beige adipocytes from lean patients as
compared to obese patients, suggesting that beige adipocyte differentiation or
activation is impaired in human obesity (Carey et al., 2014).

These studies

indicate that beige adipocytes confer beneficial metabolic properties and that loss
of beige fat function may have deleterious metabolic effects including increased
susceptibility to weight gain.
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1.3 Immune cell composition and function in lean white adipose
tissue
White adipose is a heterogeneous tissue comprised of multiple cell types
including a diverse array of immune cells. In the steady state, these immune
cells tend to be associated with the type 2 immune axis and include alternatively
activated macrophages (AAMacs), eosinophils, group 2 innate lymphoid cells
(ILC2s), invariant natural killer T (iNKT) cells, T helper type 2 (Th2) cells,
regulatory T (Treg) cells and other immune cell populations that communicate with
each other and participate in cross-talk with adipocytes. As discussed below, the
interface between immune cells and adipocytes contributes to the regulation of
lipid storage, glucose utilization, redox balance and energy expenditure (Fig. 2).
However, in the context of obesity, type 2 immune cells in WAT become
dysregulated and, in some cases, acquire a pro-inflammatory phenotype that
exacerbates adipose tissue inflammation with deleterious effects on metabolism.
In this section, we discuss emerging concepts in the composition of function of
immune cells in WAT at steady state and how changes in these immune cells in
obesity contribute to metabolic dysfunction.

1.3.1 The IL-4/Alternatively activated macrophage pathway
Alternatively activated macrophages (AAMac) are IL-4- and IL-13-dependent
cells that require Signal transducer and activator of transcription 6 (STAT6) to
maintain an alternative activation state that is distinct from the classical activation
11

state induced by interferon-γ (IFNγ) (Gordon and Martinez, 2010; Hill et al., 2014;
Martinez et al., 2009; Odegaard and Chawla, 2011; Olefsky and Glass, 2010).
AAMacs are critical for protective immunity against helminth pathogens and are
associated with pathologic allergic inflammation in the lung (Gordon and
Martinez, 2010; Martinez et al., 2009), and recent studies have implicated
AAMacs in the regulation of metabolic homeostasis (Hill et al., 2014; Odegaard
and Chawla, 2011; Olefsky and Glass, 2010). Early studies linking AAMacs to
metabolism demonstrated that macrophage-specific deletion of Peroxisome
proliferator-associated receptor (PPAR)-γ results in decreased AAMacs in WAT
in association with increased weight gain, elevated fat accumulation, impaired
glucose uptake and insulin resistance following HFD feeding (Odegaard et al.,
2007).

In addition, deletion of PPAR-δ in leukocytes also impaired AAMac

responses and was associated with increased adiposity and insulin resistance
(Odegaard et al., 2008). These loss of function studies are complemented by
gain-of-function approaches indicating that administration of exogenous IL-4 to
mice to boost AAMac responses protected mice from HFD-induced obesity and
insulin resistance (Chang et al., 2012; Ricardo-Gonzalez et al., 2010). Together,
these studies identified a critical role for the IL-4/AAMac axis in the regulation of
metabolic homeostasis.

Emerging work has revealed that AAMacs employ a diverse functional repertoire
to regulate metabolism. For example, a subset of AAMacs in WAT expresses
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genes involved in iron handling and has the capacity to store large amounts of
iron in lean mice (Orr et al., 2014). The capacity of these specialized AAMacs to
store iron is diminished in the setting of obesity, leading to accumulation of iron in
adipocytes (Orr et al., 2014) and iron-initiated production of highly toxic lipid
aldehydes that damage cellular proteins, impair adipocyte insulin sensitivity and
lead to mitochondrial dysfunction (Curtis et al., 2010; Curtis et al., 2012).
Therefore it appears that specialized iron-storing AAMacs have an essential role
in regulating iron homeostasis in WAT to maintain optimal glucose metabolism
and mitochondrial function at steady state, and that dysregulation of these cells
in obesity may have deleterious effects on glucose and energy homeostasis.
Consistent with this, treatment of obese mice with the iron chelator deferoxamine
is associated with improved glucose tolerance, decreased body weight and fat
mass, and less inflammation in fat compared to obese controls that received
vehicle (Tajima et al., 2012).

In addition, AAMacs from adipose are capable of producing catecholamines such
as norepinephrine that act on adipocytes via adrenergic receptors to stimulate
lipolysis, activate mitochondrial biogenesis and upregulate expression of
Uncoupling protein 1 (UCP1) (Fig. 2 and Fig. 3) (Liu et al., 2014; Nguyen et al.,
2011; Qiu et al., 2014; Rao et al., 2014). Recent studies suggest that AAMacs
are critical for optimal brown and beige adipocyte responses (Nguyen et al.,
2011; Qiu et al., 2014; Rao et al., 2014). Mice that lack IL-4 and IL-13 (Il4/13−/−);
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the shared receptor for these cytokines, IL-4Rα (Il4ra−/−); or STAT6, a
transcription downstream of IL-4Rα signaling (Stat6−/−) have defective AAMac
responses (Martinez et al., 2009) and exhibit decreased upregulation of UCP1
expression in BAT and impaired defense of core body temperature following
acute exposure to cold environmental temperatures (Nguyen et al., 2011). IL-4
was shown to activate AAMacs to produce catecholamines such as
norepinephrine (NE) that act on the β3 adrenergic receptor (β3AR) to stimulate
lipolysis, elicit mitochondrial biogenesis and activate UCP1 in BAT (Nguyen et
al., 2011).

However IL-4/IL-4Rα interactions do not appear to be required for BAT
responses in the context of chronic exposure to severe cold environmental
temperatures over a period of 3 days (Qui et al., 2014). In this context, AAMacs
in WAT produce NE to promote beiging of WAT (Fig. 3) (Qiu et al., 2014; Rao et
al., 2014).

Mice lacking IL4/13, STAT6 or IL-4Rα failed to undergo optimal

beiging of WAT and had decreased metabolic rate compared to wildtype controls
in the setting of chronic cold exposure (Qiu et al., 2014; Rao et al., 2014). This
phenotype appears to be mediated by macrophage-intrinsic production of
norepinephrine, as mice that lack the rate-limiting step of catecholamine
synthesis, tyrosine hydroxylase (Th), in LysM-Cre-expressing cells such as
macrophages exhibit impaired beige fat development and exhibit a 10-15%
decrease in whole body oxygen consumption in the setting of chronic exposure
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to mild (room temperature) or severe (5°C) cold environmental temperatures (Qiu
et al., 2014).

This defect in metabolic rate suggests that AAMac-derived

catecholamines might also be important for limiting weight gain. Consistent with
this, mice that lack Receptor interacting protein 140 (RIP140) had increased
AAMac responses in WAT and elicitation of beiging that was associated with
protection from diet-induced obesity (Liu et al., 2014). In addition, treatment of
mice with exogenous IL-4 elicits beiging and increases oxygen consumption
levels in an UCP1-dependent manner, effects that are associated with protection
from diet-induced obesity (Chang et al., 2012; Qiu et al., 2014; Ricardo-Gonzalez
et al., 2010).

1.3.2 Sources of IL-4 in WAT: eosinophils and invariant natural killer T
(iNKT) cells
The importance of AAMacs in regulation of metabolic homeostasis led to studies
of the sources of IL-4 in WAT. Using the 4get mouse, a reporter strain that
identifies IL-4-competent cells, it was determined that eosinophils are an
abundant immune cell population in WAT and are an important source IL-4 in this
compartment at steady state (Wu et al., 2011). Eosinophils are recruited to WAT
in the setting of chronic exposure to cold environmental temperatures, and
ΔDblGata1 mice that lack eosinophils exhibit defective beiging of WAT (Qiu et
al., 2014; Rao et al., 2014). In addition, eosinophils are decreased in WAT of
HFD-fed and genetically obese ob/ob mice (Wu et al., 2011).
15

Mice lacking

eosinophils or IL-5, which is required for eosinophil homeostasis (Rosenberg et
al., 2013; Rothenberg and Hogan, 2006), develop more severe obesity and
insulin resistance than wildtype controls in association with dysregulated AAMac
responses (Wu et al., 2011). Further, transgenic mice that constitutively
overexpress IL-5 or that were infected with helminth pathogens had increased
eosinophil accumulation in WAT and were protected from diet-induced obesity
and insulin resistance (Wu et al., 2011; Yang et al., 2013b). This indicates that
eosinophils are important regulators of metabolic homeostasis in WAT. Although
eosinophils appear to promote AAMac responses in WAT through production of
IL-4 (Wu et al., 2011; Qiu et al., 2014), whether eosinophils have other functions
in WAT such as tissue remodeling remains unknown.

In addition to eosinophils, invariant natural killer T (iNKT) cells that express lipid
antigen-specific T cell receptor variants appear to be an important source of IL-4
and IL-13 in WAT (Hams et al., 2013; Lynch et al., 2012). iNKT cells in WAT
produce more IL-4 and IL-10 and less IFN-g than do iNKT cells in the liver and
spleen (Lynch et al., 2012), suggesting that iNKT cells in WAT are in an
“alternative activation” state. Consistent with this, recent work has shown that
mammals produce endogenous αGalCer and that these endogenous lipid
antigens promote production of type 2 cytokines by iNKT cells (Kain et al., 2014),
and that adipocytes can present lipid antigen to iNKT cells (Huh et al., 2013).
iNKT cells are decreased in murine and human obesity, and surgical or dietary
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treatment of obesity restores iNKT cells in WAT (Lynch et al., 2012). Jα18deficient mice that lack iNKT cells exhibit increased body weight and adiposity
when fed a HFD compared to wildtype controls, and CD1d-deficient mice that
cannot present lipid antigen to iNKT cells develop spontaneous obesity on a low
fat diet (Lynch et al., 2012). In addition, mice lacking iNKT cells had more severe
glucose intolerance and increased pro-inflammatory macrophages in WAT
(Lynch et al., 2012), suggesting that iNKT cells are essential for limiting
inflammatory responses in the setting of obesity. Adoptive transfer of iNKT cells
induces weight loss and decreases adipocyte size while improving insulin
resistance in HFD-fed mice (Hams et al., 2013; Lynch et al., 2012), and
treatment of HFD mice with αGalCer recapitulates these effects in an iNKTdependent manner by increasing IL-4 and IL-10 production by iNKT cells (Lynch
et al., 2012). Therefore, eosinophils and iNKT cells may be important sources of
IL-4 or other factors that support AAMac function or that directly regulate
metabolic homeostasis to limit obesity and insulin resistance.

1.3.3 The IL-33/Group 2 innate lymphoid cell pathway
Group 2 innate lymphoid cells (ILC2s) are a recently described immune cell type
(Moro et al., 2009; Price et al., 2010; Neill et al. 2010) that controls eosinophil
and AAMac responses (Molofsky et al., 2013; Nussbaum et al., 2013). ILC2s are
members of a broader family of ILCs that comprise T-bet-dependent Group 1
ILCs that produce IFN-γ; GATA-3-dependent ILC3s that produce IL-5, IL-13 and
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amphiregulin; and RORγt-dependent ILC3s that produce IL-17A and IL-22 (Kim,
2014; Monticelli et al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits
and Cupedo, 2012). In barrier surfaces such as the gut and lung, ILC2s respond
to epithelial-derived cytokines IL-33, IL-25 and thymic stromal lymphopoietin
(TSLP) to initiate type 2 immune responses that protect against helminth
infection or that promote pathologic allergic inflammation (Kim, 2014; Monticelli et
al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits and Cupedo, 2012).
ILC2s were recently shown to be present in murine WAT, where these cells
constitutively produce the effector cytokines IL-5 and IL-13 to maintain eosinophil
and AAMac responses, respectively, in WAT (Molofsky et al., 2013). Strikingly,
IL-5-deficient mice exhibit decreased energy expenditure and increased obesity
compared to IL-5-sufficient controls (Molofksy et al., 2013; Wu et al., 2011).
Recent studies showed that antibody-mediated depletion of ILC2s is associated
with increased weight gain and more severe insulin resistance in mice fed a high
fat diet (Hams et al., 2013), and transferring IL-25-elicted ILC2s is sufficient to
promote weight loss in diet-induced obese mice (Hams et al., 2013).

This

suggests that ILC2s negatively regulate the development of obesity, although the
mechanisms of this remain poorly understood. One possibility is that ILC2s limit
adiposity via regulation of the eosinophil/IL-4/AAMac pathway to elicit beiging.
Future studies will be required to investigate the mechanisms by which ILC2s
regulate metabolic homeostasis.
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The cytokine IL-33 is critical for stimulating proliferation and activation of ILC2s
(Kim et al., 2014; Molofsky et al., 2013; Monticelli et al., 2011; Moro et al., 2010;
Neill et al., 2010; Price et al., 2010) and is expressed at higher levels in WAT of
obese mice and humans compared to non-obese controls (Zeyda et al., 2013).
Given that ILC2s are decreased in murine obesity (Molofsky et al., 2013), this
suggests that in the obese state ILC2s may be hypo-responsive to IL-33 or have
altered cell death, proliferation or migration. IL-33 was recently shown to be
critical for protecting mice from obesity (Miller et al., 2010). Mice lacking the IL33R exhibit increased obesity and exacerbated impairments in glucose
homeostasis following HFD feeding, and treatment of genetically obese ob/ob
mice with recombinant IL-33 limits adiposity and improves glucose metabolism in
association with enhanced AAMac responses in WAT (Miller et al., 2010).

1.3.4 CD4+ T helper cells and regulatory T cells
In addition to regulating the ILC2/eosinophil/AAMac pathway, IL-33 also acts on
adaptive immune cells such as Th2 cells (Molofsky et al., 2013) and regulatory T
cells (Tregs) (Schiering et al., 2014). Although Th2 cells are relatively rare in
WAT (Molofsky et al 2013) and remain poorly understood in the context of
obesity, Tregs in WAT have been shown to be unique members of the Treg pool
exhibiting uniquely elevated expression of PPARγ, Foxp3 and IL-10 and are
dysregulated in obese mice and humans (Cipolletta et al., 2012; Deiuliis et al.,
2011; Feuerer et al., 2009). Tregs in WAT contribute to the maintenance of insulin
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sensitivity in WAT by limiting inflammation and producing insulin-sensitizing
factors such as IL-10 (Cipolletta et al., 2012; Feuerer et al., 2009; Ilan et al.,
2010). In obesity, Tregs are decreased in both mice and humans (Cipolletta et al.,
2012; Feuerer et al., 2009; Wagner et al., 2013), and this decrease in Tregs may
be due to aberrant WAT iNKT cell responses in obese WAT (Lynch et al., 2014).
iNKT cells in WAT produce IL-2 to sustain Tregs and are an additional source of
IL-10 (Lynch et al., 2014; Lynch et al., 2012).

IL-10 suppresses Monocyte

chemotactic protein-1 (MCP-1) expression by adipocytes to limit inflammatory
macrophage infiltration of WAT and inhibits the ability of tumor necrosis factor-α
(TNF-α) to downregulate GLUT-4 expression and impair insulin action in
adipocytes (Lumeng et al., 2007). Interestingly, recent studies indicate that the
anti-diabetic class of drugs known as thiazoladinediones (TZD), which are PPARgamma agonists, ameliorate insulin resistance in obese mice via their effects on
Tregs (Cipolletta et al., 2012).

Therefore promoting Treg responses may be a

useful strategy to treat or prevent type 2 diabetes.

1.4 Immune cell responses in white adipose tissue in obesity
In obesity, white adipose tissue undergoes metabolic and inflammatory changes.
As white adipocytes accumulate triglycerides and become hypertrophic, the
vasculature in WAT becomes rarified leading to hypoxia and oxidative stress
(Curtis et al., 2010; Pasarica et al., 2009). These changes are associated with
increased adipocyte cell death and elevated production of adipocyte-derived
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inflammatory mediators, including the adipokines leptin, resistin and RBP4 (Attie
and Scherer, 2009; Greenberg and Obin, 2006; Lazar, 2007; McNelis and
Olefsky, 2014; Osborn and Olefsky, 2012; Ouchi et al., 2011). As discussed
below, these and other pro-inflammatory factors initiate a type 1 immune
response in obese WAT that is characterized by increased accumulation of CD4+
Th1 cells, CD8+ cytotoxic T cells, pro-inflammatory classically activated
macrophages (Fig. 4). These changes are discussed in this section.

1.4.1

Adipocytes, macrophages and type 1 cytokine-associated T cells

participate in a proinflammatory positive-feedback loop in obesity
In obesity adipocyte-derived inflammatory mediators such as monocyte
chemotactic protein (MCP-1), CXCL12, prostaglandins, leukotrienes and other
factors are increased and promote classically activated monocyte/macrophage
activation, proliferation and infiltration of white adipose tissue (Amano et al.,
2014; Nomiyama et al., 2007; Oh et al., 2012; Weisberg et al., 2003). These
cells engulf dying or dead adipocytes, forming crown-like structures (CLS) that
are characterized morphologically as a ring of macrophages and other immune
cells surrounding an adipocyte (Murano et al., 2008; Ouchi et al., 2011). The
formation of CLS may be an adaptive mechanism to scavenge cellular debris or
to limit the release of toxic lipid species when adipocytes undergo cell death, via
phagocytosis. However, in addition to their phagocytic roles in CLS, classically
activated macrophages in WAT of obese mice produce IL-1β, TNF-α, IFN-γ and
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IL-6 among other factors that potentiate the type 1 inflammatory response
(Lumeng et al., 2007; Nguyen et al., 2007; Zeyda et al., 2010). These cytokines
act directly on adipocytes and other cell types in distant tissues such as skeletal
muscle and liver to inhibit insulin-dependent glucose uptake (Exley et al., 2014;
Gregor and Hotamisligil, 2011; Jin et al., 2013; Osborn and Olefsky, 2012). This
pro-inflammatory process is therefore associated with the development of insulin
resistance by promoting chronic low-grade type 1 inflammation.

The accumulation of macrophages in obese WAT also appears to be regulated
by CD8+ T cells (Rausch et al., 2008).

These adaptive immune cells are

recruited to WAT before infiltration by pro-inflammatory macrophages in the
setting of high fat diet feeding (Nishimura et al., 2009). Deletion of CD8+ T cells
decreases macrophage accumulation in WAT of obese mice and ameliorates
obesity-associated insulin resistance, and adoptive transfer of CD8+ T cells to
mice fed a HFD is sufficient to promote macrophage infiltration of WAT and
exacerbate insulin resistance (Nishimura et al., 2009). In the setting of HFD
feeding, CD8+ T cells produce IFN-γ that has multiple effects on immune cells in
WAT (Revelo et al., 2014). IFN-γ acts on macrophages to upregulate expression
of pro-inflammatory effector cytokines and to increase expression of Major
histocompatibility complex class II (MHC II) (Schroder et al., 2004).

This

promotes macrophage antigen presentation to CD4+ T cells and incudes Th1
polarization and proliferation (Cho et al., 2014; Morris et al., 2013). T-bet22

dependent Th1 cells produce TNF-α and IFN-γ further potentiate insulin
resistance in WAT (Cho et al., 2014; Morris et al., 2013; Stolarczyk et al., 2013).
Thus, the CD8+ T cell/classically activated macrophage pathway in WAT appears
to be critical for downstream T helper type 1 (Th1) cell responses.

Adipocytes also appear to directly contribute to Th1 cell responses in obesity.
With increased triglyceride deposition, adipocytes upregulate their expression of
leptin, a hormone that limits food intake, as a compensatory mechanism to guard
against overly rapid weight gain (Allison and Myers, 2014).

While this is a

beneficial response to maintain energy homeostasis, in WAT leptin acts on CD4+
T cells to induce Th1 polarization and IFN-γ expression to drive a proinflammatory immune response that limits insulin sensitivity (Deng et al., 2013).
In turn, IFN-γ upregulates CIITA and MHC-II expression in adipocytes (Deng et
al., 2013) and macrophages (Cho et al., 2014; Morris et al., 2013) to adipocyte
antigen presentation to Th1 cells.

These MHC-II-mediated inflammatory

changes in obesity are critical drivers of insulin resistance (Cho et al., 2014;
Deng et al., 2013). Therefore it appears that adipocytes, macrophages, CD8+ T
cells and CD4+ Th1 cells participate in a pro-inflammatory positive-feedback loop
with deleterious consequences for WAT inflammation and glucose metabolism.
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1.4.2 Alternatively activated macrophages acquire a classical activate state
in obesity and potentiate type 1 inflammation in WAT
As discussed above, AAMacs have critical roles for regulating metabolic
homeostasis in WAT at steady state. In obesity, however, AAMacs appear to
acquire a pro-inflammatory M1-like phenotype that contributes to the
development in type 1 inflammatory responses in WAT. For example, in obesity,
AAMacs decrease their expression of IL-10 and upregulate expression of TNF-α,
IFN-γ, IL-6 and IL-1β (Han et al., 2013; Lumeng et al., 2007; Moraes-Vieira et al.,
2014). This phenotypic switch in AAMacs appears to be driven, at least in part,
by retinol binding protein 4 (RBP4) that is upregulated in obesity and that impairs
glucose homeostasis (Graham et al., 2006; Norseen et al., 2012). AAMacs from
transgenic mice that overexpress RBP4 exhibit upregulated expression of
antigen presentation machinery, TNF-α and IL-1β, and polarize CD4+ T cells in
WAT towards a Th1 phenotype characterized by increased expression of T-bet
and IFN-γ (Moraes-Vieira et al., 2014). Interestingly, this effect was not observed
in the liver, suggesting a tissue-specific effect of RBP4 on antigen presenting
cells and T cell activation (Moraes-Vieira et al., 2014). In addition, transfer of
RBP4-activated bone marrow-derived DCs (BMDCs) to lean recipient mice was
sufficient to promote Th1 cell polarization in WAT and insulin resistance
compared to unactivated BMDCs (Moraes-Vieira et al., 2014). This suggests
that AAMacs in WAT become dysregulated in the setting of obesity and acquire a
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pro-inflammatory classical activation state that supports Th1 cell polarization and
the development of insulin resistance.

1.5 Perspectives and Conclusions
Adipose tissues are diverse in their structure and function and have multiple roles
in the regulation of energy balance and weight gain (Fig. 1). WAT is essential for
triglyceride storage and regulation of glucose homeostasis, and white adipocytes
appear to link mammalian metabolic status to immune cell responses in WAT. In
addition, WAT contains beige adipocytes that have been shown to be key
regulators of energy expenditure and the development of obesity. In the lean
state WAT is populated by type 2 cytokine-associated immune cells including
AAMacs, eosinophils, ILC2s, Th2 and iNKT cells as well as anti-inflammatory
cells such as Tregs.

These immune cells participate in a complex dialog to

maintain optimal immune and adipocyte function (Fig. 2). Although the precise
mechanisms by which type 2 immune cells in WAT regulate each other, it
appears that elicitation of these cell pathways is associated with increased insulin
sensitivity, optimal adipocyte mitochondrial function and in some cases elicitation
of beige adipocytes within WAT (Fig. 3).

Conversely, disruption of these

immunologic pathways results in impaired adipocyte function characterized by
insulin resistance, oxidative stress, impaired respiratory capacity and triglyceride
deposition resulting in adipocyte hypertrophy and weight gain. Therefore, type 2
immune pathways in white adipose tissue appear to have protective roles that
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support maintenance of metabolic homeostasis and limit the development of
obesity. This implies that eliciting type 2 immune cell pathways may be a useful
strategy to treat or prevent obesity.

However in the context of obesity, the immunologic milieu of WAT undergoes a
dramatic shift from a type 2 to type 1 cytokine-associated inflammatory
environment (Fig. 4). Type 2 immune cells are decreased or dysregulated, and
in some cases acquire a pro-inflammatory phenotype (e.g. iNKT cells and
AAMacs). As type 2 immune cells tend to be associated with protection against
obesity, these alterations in type 2 cytokine-associated immunologic pathways
may contribute to the development of obesity and associated metabolic
dysfunction, and therefore subsequent type 1 inflammatory responses.

In

addition, in obesity there is recruitment of various granulocytes, monocytes and
lymphocytes to WAT. These cell types produce cytokines such as TNF-α, IFN-γ
and IL-1β among others that potentiate type 1 immune responses and enhance
antigen presentation to CD4+ T cells, polarizing these cells towards a Th1 cell
phenotype. In turn, Th1 cells produce additional TNF-α and IFN-γ, establishing a
positive-feedback loop resulting in chronic low-grade type 1 inflammation and
dysregulated glucose homeostasis. The precipitating factors that initiate type 1
immune responses in WAT are not well understood but may be related to
adipocyte cell death (Spalding et al., 2008), hypoxia (Sun et al., 2011), the
generation of toxic lipid species (Muoio and Newgard, 2006), direct effects of
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dietary lipids or carbohydrates (Calder, 2002), and translocation of commensal
bacteria to WAT (Amar et al., 2011; Cani et al., 2007) among other factors. The
apparent multifactorial nature of the type 1 immune response in WAT suggests
that targeting downstream inflammatory mediators such as IFN-γ, TNF-α or IL-1β
might have beneficial therapeutic effects in obesity-associated insulin resistance.

Finally, emerging studies have revealed complex immunomodulatory cross-talk
between the type 1 and type 2 immune systems, where type 2 inflammation
impairs type 1 responses and vice versa (Osborne et al., 2014; Reese et al.,
2014). Given the dramatic shift in the immunologic landscape within obese WAT
from a type 2 to type 1 cytokine-associated response, the effectiveness of “twofactor” immunomodulatory therapies (e.g., neutralizing TNF-α antibody plus
recombinant IL-4) should be explored as potential anti-obesity regimens.
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1.6 Figures

Figure 1. White, beige and brown adipocytes are developmentally and
functionally distinct cell populations. White and beige adipocytes arise
from a Myf5− precursor cell population that is bipotent. These preadipocytes give rise to white or beige adipocytes depending on the stimulus
and physiologic setting. White adipocytes are promoted by high fat diet
feeding or obesity and by thermoneutrality (30°C in mice).
Beige
adipocytes are elicited by β3 adrenergic receptor agonists such as
norepinephrine or epinephrine, and are recruited within WAT in the settings
of chronic exercise or exposure to cold environmental temperatures.
Although white and beige adipocytes emerge from pre-adipocytes via cell
differentiation, mature white and beige adipocytes may undergo a process
called transdifferentiation, in which one cell type acquires phenotypic
characteristics of the other. In contrast, brown adipocytes arise from a
Myf5+ precursor cell population and are present in discrete brown adipose
tissue (BAT) depots.
Despite being developmentally distinct cell
populations, beige and brown adipocytes are activated by similar
physiologic stimuli, including exercise- and cold temperature-induced
hormones and metabolites.
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Figure 2. Healthy white adipose tissue (WAT) is enriched in type 2
cytokine-associated immune cells. In the lean state, adipocytes and
endothelial cells in WAT constitutively produces interleukin (IL)-33 that can
act on Group 2 innate lymphoid cells (ILC2s) to induce production of IL-5
and IL-13 that sustain eosinophil (Eos) and alternatively activated
macrophage (AAMac) responses, respectively, in WAT. In addition,
eosinophils produce IL-4 that is necessary to maintain AAMac responses
in WAT.
AAMacs have multiple functions to maintain metabolic
homeostasis, including storing large amounts of iron, leading to
sequestration of this pro-oxidative metal cation from adipocytes to prevent
lipid peroxidation, oxidative damage to proteins and mitochondrial
dysfunction. In addition, AAMacs produce norepinephrine (NE) that acts
on both white and beige adipocytes via the β3 adrenergic receptor to
stimulate lipolysis and elicit beige adipocytes that increase metabolic rate.
In addition, adipocytes present antigen to invariant natural killer T (iNKT)
cells to elicit a unique tissue-specific anti-inflammatory phenotype
characterized by increased production of IL-4 and IL-13, which may act on
AAMacs, and IL-10. In addition, lipids from adipocytes are believed to
promote regulatory T (Treg) responses in WAT to induce production of IL10. iNKT cells are critical sources of IL-2 and are necessary to sustain
Tregs in WAT. IL-10 production by iNKT cells and Tregs promotes insulin
action in white adipocytes to facilitate maintenance of an insulin-sensitive
state. Together, these pathways contribute to metabolically healthy WAT.
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Figure 3. Immunologic
mechanisms
that
regulate beiging. In the
context
of
chronic
exposure
to
cold
environmental
temperatures or chronic
exercise, white adipose
tissue (WAT) and muscle
produce
the
adipokine/myokine
meteorin-like.
This
hormone
promotes
eosinophil
(Eos)
accumulation in WAT.
Whether other factors
contribute to increased
Eos in WAT to promote
beiging remains unknown.
Meteorin-like induces IL-4
and IL-13 production by
Eos and possibly other
cell types. IL-4 and
perhaps IL-13 act on
AAMacs
to
stimulate
norepinephrine
(NE)/
epinephrine
(Epi)
production. NE/Epi act on
the β3 adrenergic receptor
(β3AR)
to
stimulate
beiging via differentiation
and/or transdifferentiation
pathways and to activate
existing beige adipocytes,
resulting in mitochondrial
biogenesis,
Uncoupling
protein
1
(UCP1)
upregulation and UCP1dependent increases in
energy expenditure.
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Figure 4. Obese white adipose tissue (WAT) is characterized by type 1 cytokineassociated immune responses. In obese WAT, adipocyte hypertrophy is associated with
hypoxia and adipocyte cell death. Dead and neighboring adipocytes produce proinflammatory signals such as Monocyte chemotractant protein 1 (MCP1), C-X-C motif
chemokine 12 (CXCL12), Retinol binding protein 4 (RBP4) and Resistin that are associated
with the recruitment of classically activated macrophages (MP) into WAT and MP activation.
MP accumulation in WAT is also mediated by pro-inflammatory invariant natural killer T
(iNKT) cells that exhibit impaired production of interleukin (IL)-10 and upregulated
+
production of Tumor necrosis factor-α (TNF-α), and by CD8 cytotoxic T cells that produce
Interferon (IFN)-γ. These factors also promote MP activation and upregulate Major
histocompatibility complex class II (MHC II) on MP and adipocytes. MHC II-mediated
+
antigen presentation by MP and adipocytes stimulates polarization of CD4 T cells towards a
T helper type 1 (Th1) phenotype. Supporting this process are TNF-α, IFN-γ, IL-1β and IL-6
produced by MP cells, dysregulated alternatively activated macrophages (AAMacs), iNKT
+
cells and CD8 T cells. In addition, leptin is upregulated in obese WAT, and this factor also
+
promotes Th1 cell polarization. MP cells, CD8 T cells and Th1 cells collectively interact to
form crown-like structures (CLS) to facilitate phagocytosis of dead adipocytes. This process
further promotes antigen presentation and type 1 immune responses, establishing a vicious
cycle. Type 1 cytokines such as TNF-α and IFN-γ act directly on adipocytes to impair insulin
action, leading to insulin resistance. Dysregulated AAMacs also produce type 1 cytokines in
the setting of obesity to contribute to insulin resistance. AAMacs also lose their capacity to
store iron, resulting in redistribution of iron to adipocytes. This results in iron-initiated lipid
peroxidation that causes reactive oxygen species (ROS) production, insulin resistance and
mitochondrial dysfunction. In addition, AAMacs in obese WAT promote collagen deposition
in WAT and fibrosis, leading ultimately to exacerbated hypoxia and inflammation and
potentiation of the type 1 immune response. These processes occur in the setting of
decreased abundance of regulatory T cell (Treg), Group 2 innate lymphoid cell (ILC2) and
eosinophils (Eos) that promote insulin sensitivity and metabolic homeostasis in WAT in the
steady state.
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Chapter 2: Group 2 innate lymphoid cells are
dysregulated in human and murine obesity and are
regulated by IL-33
2.1 Abstract
In obesity there is a shift from type 2 to type 1 cytokine-associated immune
responses in white adipose tissue (WAT) that promote insulin resistance. In
addition, emerging studies indicate that type 2 immune cells such as eosinophils
and alternatively activated macrophages that limit weight gain become
dysregulated in obese WAT, suggesting that decreased type 2 immune
responses in WAT may contribute to the development of obesity.

Group 2

innate lymphoid cells (ILC2s) were recently identified in murine white adipose
tissue (WAT), where they produce interleukin (IL)-5 and IL-13 to maintain
eosinophil and AAMac responses in WAT and limit the development of obesity.
However, ILC2s have not been identified in human adipose tissue, and the
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factors that control ILC2 responses in WAT remain poorly characterized. Here,
we identify IL-33 receptor+ ILC2s in human WAT and demonstrate that
decreased ILC2 populations in WAT are a conserved characteristic of obesity in
humans and mice. Employing loss-of-function studies in mice, we demonstrate
that endogenous IL-33 is necessary to maintain normal ILC2 frequencies,
numbers and effector cytokine production.

IL-33-deficient mice exhibited

increased adiposity and impaired glucose homeostasis compared to IL-33sufficient controls. In gain-of-function studies, administering recombinant murine
(rm)IL-33 to mice resulted in increased ILC2 accumulation in WAT and
ameliorated obesity and glucose intolerance in mice fed a HFD.

rmIL-33

treatment was associated with increased caloric expenditure without affecting
food intake, suggesting that IL-33 treatment influences body weight by regulating
metabolic rate. Collectively, these data indicate that IL-33 is critical for regulating
ILC2 responses in WAT and for limiting adiposity, and suggest that the IL33/ILC2 pathway may be dysregulated in the context of human and murine
obesity.

2.2 Introduction
Obesity is an increasingly prevalent metabolic disease characterized by
accumulation of excess adipose tissue and insulin resistance (Ogden et al.,
2012; Pi-Sunyer, 1999). Genetic and environmental factors contribute to the
development of obesity, and emerging studies indicate that the immune system
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also regulates weight gain and insulin resistance (Bouchard, 2008; Gregor and
Hotamisligil, 2011; Lumeng and Saltiel, 2011; Odegaard and Chawla, 2013b;
Osborn and Olefsky, 2012). This implies that dissecting the complex interactions
between immune and metabolic systems will be important for understanding the
biology underlying obesity and how current and future therapeutics might
influence metabolism.

Recent studies indicate that type 2 cytokine-associated immune cells such as
alternatively activated macrophages (AAMacs) and eosinophils can regulate
metabolic homeostasis. For example, mice with impaired AAMac responses are
more susceptible to diet-induced obesity than mice with normal AAMac
responses (Odegaard et al., 2007; Odegaard et al., 2008; Ricardo-Gonzalez et
al., 2010). In addition, treatment of mice with recombinant IL-4, which induces
and maintains AAMac polarization (Martinez et al., 2009), protects mice from the
development of obesity (Chang et al., 2012; Ricardo-Gonzalez et al., 2010).
Eosinophils are the dominant IL-4-producing cell type in white adipose issue
(WAT) (Wu et al., 2011). These innate immune cells are dependent on IL-5 and
are traditionally viewed as being end-stage effector cells with critical roles in
protective immunity to parasitic helminth infection and pathologic roles in allergic
lung inflammation (Rosenberg et al., 2013; Rothenberg and Hogan, 2006).
However in WAT, eosinophils are abundant immune cells with homeostatic
functions that control weight gain (Wu et al., 2011). For example, mice lacking
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eosinophils or IL-5 develop more severe obesity than wildtype controls, and IL-5transgenic hypereosinophilic mice are protected from diet-induced obesity
(Molofsky et al., 2013; Wu et al., 2011). Further, parasitic helminth infection with
the hookworm Nippostrongylus brasiliensis results in eosinophil accumulation in
WAT and decreases obesity in mice fed a high fat diet (HFD) (Wu et al., 2011;
Yang et al., 2013b). These studies indicate that eosinophils, a terminal type 2
effector cell population, are important for regulation of weight gain in mice.

Group 2 innate lymphoid cells (ILC2s) are recently described innate immune cells
that initiate type 2 immune responses by producing large amounts of the type 2
cytokines IL-5 and IL-13 to control eosinophil and AAMac responses (Molofsky et
al., 2013; Moro et al., 2010; Neill et al., 2010; Nussbaum et al., 2013; Price et al.,
2010). ILC2s are dependent on the transcription factors Inhibitor of DNA binding
2 (Id2) and T cell factor 1 (TCF1, also known as TCF7) as well as the common
gamma chain (γc, also known as IL-2Rγ) among other factors (Monticelli et al.,
2011; Moro et al., 2010; Neill et al., 2010; Yang et al., 2013a). In addition, ILC2s
are developmentally and functionally dependent on GATA binding protein 3
(GATA-3), which is essential for IL-5 and IL-13 production by ILC2s (Furusawa et
al., 2013; Klein Wolterink et al., 2013; Mjosberg et al., 2012). ILC2s are activated
by the epithelial cell-derived cytokines IL-33, IL-25 and thymic stromal
lymphopoietin (TLSP) to elicit type 2 immune responses important for helminth
parasite expulsion and allergic inflammation (Hong et al., 2014; Kim et al., 2013;
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Kim et al., 2014; McSorley et al., 2014; Moro et al., 2010; Neill et al., 2010; Price
et al., 2010; Roediger et al., 2013; Yang et al., 2013a).

Recent studies have also implicated ILC2s in the regulation of obesity (Hams et
al., 2013; Molofsky et al., 2013). Mice fed a HFD for 12 weeks are reported to
have decreased frequencies and numbers of ILC2s in association with impaired
eosinophil and AAMac responses in WAT (Molofsky et al., 2013). In addition,
treatment of HFD-fed lymphocyte-deficient mice with anti-CD90.2 monoclonal
antibody was associated with decreased ILC2s in WAT as well as increased
weight gain and worsened insulin resistance compared to mice receiving control
immunoglobulin (Hams et al., 2013). Gain-of-function studies also indicate that
adoptive transfer of IL-25-elicited ILC2s sort-purified from peritoneal exudate
cells (PECs) is associated with weight loss in HFD-fed mice (Hams et al., 2013).
Collectively, these studies indicate that ILC2s may be dysregulated in obese
mice and that ILC2s may act to limit the development of obesity.

However,

ILC2s have not been identified in human WAT, and whether ILC2s are
dysregulated in human obesity remains unknown.

In addition, the upstream

factors that regulate ILC2 responses in WAT remain poorly understood.

Data presented in this Chapter identify IL-33 receptor (IL-33R)+ ILC2s in human
and murine WAT and demonstrate that ILC2 populations are decreased in both
human and murine obesity. It is also shown that IL-33 critically regulates ILC2
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responses in WAT and the development of obesity in mice. IL-33-deficient mice
had decreased frequencies and numbers of ILC2s in epididymal (E)-WAT and
inguinal i(WAT) and exhibited impaired ILC2-derived IL-5 and IL-13 expression.
When fed a normal low fat diet, IL-33-deficient mice developed spontaneous
weight gain and accumulation of fat mass and were insulin resistant.
Additionally, treatment of HFD-fed mice with recombinant IL-33 increased ILC2
accumulation in WAT and abrogated HFD-induced increases in fat mass and
glucose intolerance. IL-33 treatment decreased whole body adiposity in lean
mice, and this was associated with increased caloric expenditure. Collectively,
results presented in this Chapter indicate that decreased ILC2 populations in
WAT is a conserved characteristic of obesity in mice and humans and implicate
the IL-33/ILC2 axis in the regulation of metabolic rate to limit the development of
obesity in mice.

2.3 Methods
2.3.1 Mice
C57BL/6 and Rag1−/− mice were obtained from Jackson Labs. Il33+/+ mice were
obtained from Taconic, and Il33−/− mice were obtained from Amgen Inc via
Taconic. Id2-/- bone marrow chimeras (Monticelli et al., 2011) and Tcf7-/- mice
(Yang et al., 2013a) were generated as described previously. For Id2-deficient
bone marrow chimeras, 10-20 x 106 bone marrow cells from congenically marked
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Id2+/+ (CD45.1+ CD45.2−) or Id2−/− (CD45.1− CD45.2+) fetal liver chimeras were
transferred by intravenous injection into lethally irradiated wildtype hosts (900
RAD) of a unique congenic marker combination (CD45.1+ CD45.2+) (Monticelli et
al., 2011). All mice were males and had ad libitum access to food and water and
were maintained in a specific pathogen free facility with a 12h:12h light:dark
cycle (lights on at 7:00 AM, lights off at 7:00 PM).

Animals were randomly

assigned to groups of n=3-5 mice per group per experiment, and at least two
independent experiments were performed throughout. In all in vivo experiments,
a single technical replicate per mouse was performed except in glucose
homeostasis tests described below, in which 2-4 technical replicates were
performed per mouse for each time point.

For all in vitro experiments, 2-3

technical replicates were performed in each independent experiment. Sample
sizes in each independent experiment were selected to have power of at least
90% using published sample size/power formulas (Brestoff and Van den Broeck,
2013). All experiments were carried out under the guidelines of the Institutional
Animal Care and Use Committee at the University of Pennsylvania.

2.3.2 Human samples
Subcutaneous white adipose tissue (S-WAT) from the abdominal region was
obtained from human donors via the New York Human Organ Donor Network
(NYODN) and via the Cooperative Human Tissue Network (CHTN) Eastern
Division, University of Pennsylvania. NOYDN samples were from recently
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deceased organ donors at the time of organ acquisition for clinical transplantation
through an approved research protocol and MTA with the NYODN. All NYODN
donors were free of cancer and were Hepatitis B-, Hepatitis C-, and HIVnegative. Tissues were collected after the donor organs were flushed with cold
preservation solution and clinical procurement process was completed. Samples
from CHTN were collected from non-deceased adults undergoing surgery for
other purposes (e.g. elective panniculectomies), and were harvested from
discarded connective tissue by CHTN staff. All human samples from NYODN
and CHTN were stored in DMEM on ice or at 4°C for 24-48 hours before
processing.

Donors were defined as non-obese if their body mass index (BMI) was < 30.0
kg/m2 (n=7) or obese if their BMI was ≥ 30.0 kg/m2 (n=7). Sample sizes per
group were selected to have power >95% using published sample size/power
formulas (Brestoff and Van den Broeck, 2013). There were no differences in the
proportion of donors from NYODN or CHTN between non-obese and obese
groups (Table 1). ILC2 frequencies were also compared for all characteristics
shown in Table 1, and those characteristics that had a P-value < 0.10 were
interrogated to test whether they could explain the differences in ILC2
frequencies observed between non-obese vs obese donors. The human samples
from NYODN do not qualify as “human subjects” research, as confirmed by the
Columbia University IRB, and the human samples from CHTN were de-identified
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and were not obtained for the specific purpose of these studies and therefore are
not considered “human subjects” research.

2.3.3 Rodent chow and diet-induced obesity
In all experiments, mice had ad libitum access to food and water. Where
indicated, mice were fed a control diet (CD, 10% kcal fat, Research Diets, New
Brunswick, New Jersey) or high fat diet (HFD, 45% or 60% kcal fat as indicated,
Research Diets) for the indicated period of time starting at 6-8 weeks of age.
CD, 45% HFD and 60% HFD were gamma-irradiated (10-20 kGy) and stored at 4
°C under dry conditions until use, and rodents were provided fresh chow weekly.
In all experiments that did not employ CD or HFD, mice were fed a standard
autoclavable rodent chow (5% kcal fat, #5010, Lab Diets, St. Louis, Missouri) that
had been autoclaved and allowed to cool overnight before use.

2.3.4 In vivo cytokine treatments
Mice were administered 12.5 µg/kg carrier-free recombinant murine IL-33 (rmIL33, R&D Systems, Minneapolis, Minnesota) in sterile phosphate buffered saline
(PBS) by intraperitoneal (i.p.) injection daily for the indicated number of days. In
HFD studies, mice were treated with 12.5 µg/kg recombinant murine IL-33 or
PBS once every 4 days by i.p. injection. All injections were performed between
the hours of 4:00 PM and 7:00 PM.
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2.3.5 In vivo metabolic phenotyping
Mice were single-housed in an OxyMax Comprehensive Laboratory Animal
Monitoring System (CLAMS, Columbus Instruments, Columbus, Ohio) for 24
hours.

Mice were acclimated to the CLAMS cages for 24 hours before

measurements commenced. Caloric expenditure (kcal/hour) was measured by
indirect calorimetry. Food intake was also measured throughout the 24 hour
period.

Fat mass and adiposity were measured by

1

H-nuclear magnetic

resonance (NMR) spectroscopy.

For glucose tolerance tests, mice were fasted overnight for 14-16 hours (h) and
injected with 2 g/kg D-glucose by i.p. injection. Blood glucose values were
measured just prior to injection (time 0) and at 20, 40, 60, 90 and 120 minutes
(min) post-injection. For insulin tolerance tests, mice were fasted for 4-6h and
then injected with bovine insulin (0.5 U/kg). Blood glucose values were measured
just prior to injection (time 0) and at 20, 40 and 60 min post-injection.

To

measure fasting blood glucose and insulin concentrations, mice were fasted
overnight for 14-16 hours, and blood glucose values were measured followed by
collection of approximately 20-30 µL blood for serum insulin concentration
determination using the Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem).
Homeostatic model assessment of insulin resistance (HOMA-IR) index values
were calculated as described previously (Matthews et al., 1985). All blood
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glucose measurements were performed using FreeStyle Lite handheld
glucometer (Abbott) in duplicate or triplicate.

2.3.6 Adipocyte area quantification.
Inguinal white adipose tissue (iWAT) sections were H&E stained and imaged at
40X magnification. White adipocyte area was calculated using ImageJ software
by drawing ellipses circumscribing white adipocytes. The scale was set to 8
pixels per micron based on the pixel length of a 100 µm scale bar at 40X
magnification.

Two-to-three images, each from a different area of a given

sample, were captured per animal. Adipocyte area was measured in 10-20
adipocytes per image (25-40 adipocytes per mouse) and averaged on a per
mouse basis.

2.3.7 Isolation of immune cells from adipose
Murine epididymal white adipose tissue (E-WAT), inguinal WAT (iWAT) or brown
adipose tissue (BAT) or human subcutaneous abdominal WAT were harvested
and dissected so as to be free of reproductive tissues, lymph nodes and fibrous
connective tissue. Tissues were finely minced using sterile scissors to form a
slurry that was subsequently digested with 0.1% collagenase type II (SigmaAldrich, USA) in high glucose DMEM at 37°C with shaking at 200 rpm for 60-90
min at a 45° angle. Digested tissues were filtered through a 70 µm nylon mesh.
The mesh was washed with approximately 20 mL Wash Media (high glucose
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DMEM supplemented with 5% heat-inactivated fetal bovine serum [FBS], 100
units/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine). All Wash
Media reagents were from Life Technologies (Grand Island, NY) except FBS,
which was from Denville Scientific (South Plainfield, NJ). Washed cells were
centrifuged at 500 x g for 5 min at 4°C, and then floating adipocytes were
removed by aspiration and the stromal vascular fraction (SVF) pellet was
resuspended in red blood cell lysis buffer (ACK RBC Lysis Buffer) and allowed to
incubate at room temperature for 2 min. The RBC Lysis reaction was stopped by
addition of 10 volumes Wash Media, and the SVF cells were recovered by
centrifugation at 500 x g for 5 min at 4°C. Cells were resuspended in 200 µL
Wash Media and aliquotted in equal parts for immediate flow cytometric analysis
or for re-stimulation as described below for subsequent intracellular cytokine
analysis by flow cytometry. In some experiments, all recovered SVF cells were
used for immediate flow cytometric analyses.

2.3.8

Surface and nuclear staining of murine cells for flow cytometric

analyses
Isolated SVF cells from mice were resuspended in 100 µL FACS PBS (sterile 1X
phosphate buffered saline [Invitrogen] supplemented with 2% heat-inactivated
FBS and 1 mM EDTA [Invitrogen]) containing LIVE/DEAD Fixable Aqua Dead
Cell Stain (1:600) and anti-mouse IL-33R-biotin (T1/S2, clone DJ8) from MD
Bioproducts (St. Paul, MN) (1:300). Cells were incubated on ice for 30 min in the
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dark and were washed twice in 250 µL FACS PBS with centrifugation at 500 x g
for 5 min at 4°C before each wash.

Washed cells were stained with

combinations of the following antibodies (all of which were used at 1:300 dilutions
unless otherwise noted) in a volume of 90 µL staining buffer (FACS PBS
supplemented with 20 µg/mL rat IgG): anti-mouse CD45-eFluor 605NC (clone
30-F11; 1:200), CD45.1-eFluor 450 (A20; 1:100), CD45.2-AlexaFluor 700 (104),
F4/80-eFluor 450 (BM8), CD3e-PerCP-Cy5.5 (145-2C11), CD5-PerCP-Cy5.5
(53-7.3), CD19-PerCP-Cy5.5 (1D3), NK1.1-PerCP-Cy5.5 (PK136), CD11cPerCP-Cy5.5 (N418), FcεRIα-FITC (MAR-1), Foxp3-FITC (FJK-16s; 1:100),
GATA-3-PE (TWAJ; 1:100) and CD25-PE-Cy7 (clone PC61.5) from eBioscience
(San

Diego,

CA);

CD11b-PE-Texas

Red

(M1/70.15;

1:500)

from

Life

Technologies (Grand Island, NY); CD90.2-Alexa Fluor 700 (30-H12; 1:400) and
CD4-Brilliant Violet-650 (RM4-5) from BioLegend (San Diego, CA); SiglecF-PE
(E50-2440) and CD3e-PE-CF594 (145-2C11) from BD Biosciences (San Jose,
CA); CD206-Alexa Fluor 647 (MR5D3; 1:200) from AbD Serotec (Raleigh, NC);
and Streptavidin-APC (1:300) from eBioscience. Foxp3, GATA-3 and CD206
staining was performed following fixation and permeabilization with the Foxp3
Staining Buffer Set (eBioscience) according to the manufacturer’s protocol. All
intracellular stains were performed in 1X Permeabilization Buffer (PB,
eBioscience) for 45 min on ice. Cells were washed 3 times in 250 µL 1X PB with
centrifugation at 500 x g for 5 minutes at 4 °C between washes, and recovered
cells were resuspended in 200 µL FACS Buffer before flow cytometric analyses.
44

2.3.9

Surface and nuclear staining of human cells for flow cytometric

analyses
Isolated SVF cells from human tissues were resuspended in 100 µL FACS PBS
(sterile 1X phosphate buffered saline [Invitrogen] supplemented with 2% heatinactivated FBS and 1 mM EDTA [Invitrogen]) containing LIVE/DEAD Fixable
Aqua Dead Cell Stain (1:600) and anti-human FcεRIα-biotin (AER-37;
eBioscience; 1:100). Cells were incubated on ice for 30 min in the dark and were
washed twice in 250 µL FACS PBS with centrifugation at 500 x g for 5 min at 4°C
before each wash. Washed cells were stained with combinations of the following
antibodies in a volume of 90 µL FACS PBS (all of which were used at 1:100
dilutions unless otherwise noted): anti-human GATA-3-PE (TWAJ), TCRαβPerCP-Cy5.5 (IP26), CD5-PerCP-Cyanin5.5 (L17F12), CD19-Alexa Fluor 700
(HIB19), CD11c-Alexa Fluor 700 (3.9), CD127-eFluor 780 (eBioRDR5; 1:50),
CD45-eFluor 605NC (HI30; 1:50), FcεRIα-biotin (AER-37) and StreptavidineFluor 650NC from eBioscience; CD56-Alexa Fluor 700 (B159), CD16-Alexa
Fluor 700 (3G8), CD3 (SP34-2) and CD25-PE-Cy7 (M-A251; 1:50) from BD
Pharmingen; CD11b-PE-Texas Red (M1/70.15; 1:300) from Life Technologies;
and ST2L-FITC (B4E6; 1:50) from MD Bioproducts. GATA-3 and CD3 staining
was performed following fixation and permeabilization with the Foxp3 Staining
Buffer Set (eBioscience) according to the manufacturer’s protocol.

All

intracellular stains were performed in 1X Permeabilization Buffer (PB,
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eBioscience) for 45 min on ice. Cells were washed 3 times in 250 µL 1X PB with
centrifugation at 500 x g for 5 minutes at 4 °C between washes, and recovered
cells were resuspended in 200 µL FACS Buffer before flow cytometric analyses.

2.3.10 Intracellular cytokine analysis
To examine ILC2 effector cytokine production, single cell suspensions of E-WAT
or iWAT SVF were stimulated for 4 hours ex vivo with Phorbol 12-myristate 13acetate (PMA) (100 ng/mL) and ionomycin (1 ng/mL) in the presence of Brefeldin
A (10 µg/mL) (all from Sigma-Aldrich) in a 37°C incubator (5% CO2). Cells were
then surface stained and fixed/permeabilized using Cyto Fix/Perm (BD
Pharmingen) according to manufacturer’s instructions before intracellular staining
for IL-5 (APC-IL-5, clone TRFK5, 1:200, eBioscience) and IL-13 (PE-IL-13,
eBio13A, 1:200, eBioscience). All intracellular stains were performed in 90 µL 1X
Permeabilization Buffer (PB, eBioscience) for 45 min on ice.

After each

intracellular stain, cells were washed 3 times in 250 µL 1X PB with centrifugation
at 500 x g for 5 minutes at 4°C between washes. Recovered cells after the final
wash were resuspended in 200 µL FACS Buffer before flow cytometric analyses.

2.3.11 Flow cytometry
For all flow cytometry analyses, stained cells were acquired on a BD LSRII flow
cytometer (BD Biosciences). The entirety of each sample was acquired to obtain
total cell counts, which were subsequently normalized to tissue weight. Flow
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cytometry data were analyzed using FlowJo software version 9.6.4 (Tree Star,
Inc.).

2.3.12 Statistical analyses
Data are expressed as mean ± standard error of the mean (SEM). Statistical
significance was determined for Normally-distributed data by using the two-tailed
Student’s t test or a one-way or two-way analysis of variance (ANOVA) followed
by Sidak or Tukey post-hoc tests.

If variance differed between groups, the

appropriate statistical correction was applies (e.g. Welch’s correction).
Correlation analyses were conducted using Pearson linear regression.
Proportions among human samples were compared by Chi-squared tests.
Significance was set at P<0.05. Statistical analyses were performed with Prism 6
(GraphPad Software, Inc.) or SPSS Statistics version 22 (IBM).

2.4 Results
2.4.1 Identification of ILC2s in human and murine white adipose tissue
To address whether ILC2s are present in human and murine WAT, we first
obtained abdominal subcutaneous white adipose tissues (WAT) from non-obese
human donors and identified a lineage (Lin)-negative cell population that
expresses CD25 (IL-2Rα) and CD127 (IL-7Rα) (Fig. 5a,b). This cell population
was positive for GATA binding protein 3 (GATA-3) and the IL-33 receptor (IL47

33R) (Fig. 5c), a phenotype that is consistent with ILC2s identified in other
human tissues (Kim et al., 2013; Mjosberg et al., 2012; Mjosberg et al., 2011;
Monticelli et al., 2011).

A Lin− CD25+ CD127+ cell population (Fig. 6a) that

expresses CD90, GATA-3 and IL-33R but not CCR6 (Fig. 6b) was also identified
in epididymal WAT (E-WAT) of mice, similar to murine ILC2s described
previously (Furusawa et al., 2013; Molofsky et al., 2013; Monticelli et al., 2011;
Moro et al., 2010; Neill et al., 2010; Price et al., 2010; Saenz et al., 2013). In
mice, Lin− CD25+ CD127+ cells in E-WAT were developmentally dependent on
Id2, TCF-7 and γc (Fig. 7a-c), indicating that these cells exhibit a developmental
profile similar to ILC2s described in other murine tissues (Monticelli et al., 2011;
Moro et al., 2010; Neill et al., 2010; Yang et al., 2013a). In addition, Lin− CD25+
CD127+ cells from murine E-WAT produced the type 2 effector cytokines IL-5
and IL-13 (Fig. 7d). Collectively, these data identify ILC2s in human and murine
WAT and indicate that murine E-WAT ILC2s exhibit phenotypic, developmental
and functional similarities to ILC2s found in other mammalian tissues.

2.4.2

Obesity is associated with decreased ILC2 populations in white

adipose tissue in both mice and humans
To examine whether human ILC2 responses are dysregulated in the setting of
obesity, we compared ILC2 frequencies in abdominal subcutaneous WAT from
non-obese versus obese donors (Table 1). Donors were categorized as nonobese (n=7) if their body mass index (BMI) was less than 30.0 kg/m2 or as obese
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if their BMI was greater than or equal to 30.0 kg/m2 (n=7), a standardized
threshold for defining an individual as clinically obese (Flegal et al., 2014).
Strikingly, WAT from obese donors exhibited significantly decreased frequencies
of ILC2s compared to non-obese controls (Fig. 8a,b).

In linear regression

analyses ILC2 frequencies in WAT were also inversely correlated with BMI (Fig.
8c). These findings suggest that ILC2s in WAT are decreased human obesity
compared to the non-obese state.

To examine the association between human ILC2 frequencies in WAT and
obesity, potential confounding variables including source of tissue, age, sex and
some co-morbidities were analyzed to determine whether these factors might
explain observed differences in ILC2 frequencies (Table 1). As tissues were
obtained from the New York Organ Donor Network (NYODN) and the
Cooperative Human Tissue Network-Eastern Division (CHTN), the source of
tissue was assessed. The obese donors from each source tended to have lower
WAT ILC2 frequencies compared to non-obese donors from the same source
(Fig. 9a). Although WAT ILC2 frequencies in obese donors tended to be lower in
obese donors from CHTN vs NYODN (Fig. 9a), this difference appeared to be
explained by higher BMI values in the obese group from CHTN (Fig. 9b).

In addition, analyses showed that the obese donors were significantly older than
the non-obese donors (Table 1, P=0.042). Therefore, we performed additional
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analyses comparing WAT ILC2 frequencies between the younger 50%ile (n=7,
36.0 +/- 3.5 years) and the older 50%ile (n=7, 55.9 +/- 1.9 years). WAT ILC2
frequencies did not differ according to age groups (P=0.71, Fig. 10a), indicating
that age does not explain differences observed in WAT ILC frequencies between
non-obese and obese donors. In addition, the obese donors were predominantly
females (6 of 7 donors) in contrast to the non-obese donors (3 of 7 donors)
(Table 1, P=0.094). This distribution of biological sex precluded comparisons of
ILC2 frequencies in males vs females, and analyzes comparing non-obese
versus obese WAT ILC2 frequencies in only males were not possible due to
small sample sizes in the obese group. However, when analyses were restricted
to females only, WAT ILC2 frequencies remained significantly decreased in
obese vs non-obese donors (Fig. 10b). These results suggest that biological sex
also does not explain differences observed in WAT ILC frequencies between
non-obese and obese donors. The non-obese and obese donors did not differ
significantly for history of type 2 diabetes, liver disease or cardiovascular disease
(Table 1), suggesting that these co-morbidities also do not explain differences
observed in WAT ILC2 frequencies between non-obese and obese donors.

Next, to test whether ILC2s in WAT are also dysregulated in murine obesity, mice
were fed a control diet (CD) or high fat diet (HFD). HFD feeding was associated
decreased frequencies and numbers of ILC2s in E-WAT of HFD-fed mice
compared to CD-fed controls (Fig. 11a,b). These data indicate that ILC2s are
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also decreased in WAT of diet-induced obese mice and suggest that decreased
ILC2 populations are a conserved characteristic of obesity in mice and humans.

2.4.3 Endogenous IL-33 sustains ILC2 responses in WAT and limits the
development of spontaneous obesity
Previous studies demonstrated that IL-33 promotes ILC2 responses in WAT and
other murine tissues in inflammatory settings (Furusawa et al., 2013; Imai et al.,
2013; Molofsky et al., 2013; Monticelli et al., 2011; Moro et al., 2010; Neill et al.,
2010; Saenz et al., 2013), however it is unclear whether IL-33 regulates basal
ILC2 responses. We therefore employed IL-33-deficient mice to test whether
endogenous IL-33 regulates ILC2 responses. Strikingly, Il33−/− mice exhibited
decreased frequencies and numbers of ILC2s in E-WAT (Fig. 12a) and iWAT
(Fig. 12b) compared to Il33+/+ controls at steady state. Further, expression of IL5 and IL-13 by ILC2s from E-WAT or iWAT was decreased in Il33−/− mice
compared to controls (Fig. 13). These data indicate that endogenous IL-33 is
required to maintain normal ILC2 frequencies and numbers and functional
potential in WAT.

As ILC2s have previously been implicated in limiting weight gain in the context of
HFD feeding and in enhancing glucose homeostasis (Hams et al, 2013), we next
sought to test whether IL-33-deficient mice exhibited abnormal metabolic
homeostasis under basal conditions.

Male IL-33-deficient or -sufficient mice
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were fed a CD (10% kcal fat) starting at 7 weeks of age for a period of 12 weeks.
Strikingly, over the first 10 weeks of the feeding regimen, mice lacking IL-33
gained more weight than controls in terms of absolute and relative mass (Fig.
14a,b). This was associated with increased E-WAT and iWAT accumulation (Fig.
14c), increased white adipocyte size (Fig. 14d) and higher whole body adiposity
(Fig. 14e) in IL-33-deficient mice compared controls. In addition, Il33−/− mice
exhibited impaired glucose homeostasis as evidenced by fasting euglycemic
hyperinsulinemia (Fig. 15a,b), increased homeostatic model assessment of
insulin resistance (HOMA-IR) index values (Fig. 15c), impaired glucose tolerance
(Fig. 15d) and impaired insulin tolerance (Fig. 15e). Together, these results
indicate that endogenous IL-33 is required to maintain normal ILC2 responses in
WAT and to limit the development of spontaneous obesity.

2.4.4 Recombinant IL-33 treatment elicits ILC2 responses in white adipose
tissue and decreases adiposity
We next employed a complementary gain-of-function approach to examine
whether IL-33 treatment could elicit ILC2 responses in WAT of HFD-fed mice and
limit the development of obesity. Mice were fed a CD or HFD for 4 weeks, and
HFD-fed mice were treated with PBS or rmIL-33 once every 4 days starting on
the first day of the feeding regimen. At this early time point (4 weeks), HFD-fed
mice treated with PBS exhibited decreased ILC2 numbers in E-WAT compared
to controls (Fig. 16a), a result that is similar to longer HFD feeding regimens (Fig
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11b). Further, rmIL-33 treatment was associated with markedly increased ILC2
numbers in E-WAT (Fig. 16a), indicating that rmIL-33 treatment produced a
robust ILC2 response in the setting of HFD feeding. Strikingly, HFD mice treated
with rmIL-33 exhibited decreased body weight (Fig. 16b) and lower accumulation
of E-WAT and iWAT mass (Fig. 16c,d) compared to HFD mice treated with PBS.
These changes were associated with improved fasting blood glucose levels (Fig.
16e) and enhanced glucose tolerance (Fig. 16f). Collectively, these data indicate
that exogenous IL-33 can promote ILC2 responses and ameliorate HFD-induced
obesity in association with improved glucose tolerance.

We next tested whether rmIL-33 treatment for 7 days could decrease adiposity in
lean mice. As expected, rmIL-33 treatment resulted in increased frequencies
and numbers of ILC2s in E-WAT (Fig. 17a) and iWAT (Fig. 17b). Although body
weight did not differ between groups (Fig. 17c), mice treated with rmIL-33 had
significantly decreased whole body adiposity compared to controls (Fig. 17d),
indicating that exogenous rmIL-33 can decrease fat mass in lean mice.

2.4.5 Recombinant IL-33 treatment increases caloric expenditure of mice
To examine the mechanisms by which IL-33 regulates adiposity, we assessed
energy homeostasis in lean mice treated with PBS or rmIL-33 daily for 7 day and
employed Comprehensive Laboratory Animal Monitoring System (CLAMS) cages
to simultaneously assess caloric expenditure and intake during days 6-to-7 over
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a 24 hour period. rmIL-33 treatment resulted in a significantly increased caloric
expenditure compared to controls (Fig. 17e). However, rmIL-33 treatment did not
result in altered food intake (Fig. 18a). The absence of hyperphagia in the setting
of increased caloric expenditure, as observed in this experimental system,
appeared to be related to decreased ambulatory activity levels. Supporting this,
mice treated with rmIL-33 exhibited decreased ambulatory activity compared to
controls (Fig. 18b). In addition, decreases in ambulatory activity over 15 min
intervals in rmIL-33- vs PBS-treated mice were significantly correlated with
decreased food intake over the same time intervals in rmIL-33- vs PBS-treated
mice (Fig. 18c).

Taken together, these data suggest that increased caloric

expenditure in rmIL-33-treated mice could not be explained by the thermic effect
of food or physical activity levels but was regulated by other physiologic
processes.

2.5 Discussion
Data presented in this Chapter identify IL-33R+ ILC2s in human and murine WAT
and demonstrate that decreased ILC2 populations in WAT is a conserved
characteristic of obesity in both humans and mice. Furthermore, this Chapter
demonstrates that IL-33 is critical for regulating ILC2 responses in WAT and for
limiting obesity in mice. Mice lacking IL-33 had impaired ILC2 responses and
developed spontaneous obesity on a low fat diet. Further, treatment of HFD-fed
wildtype mice with recombinant murine IL-33 increased ILC2 accumulation in
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WAT and ameliorated the development of obesity. IL-33-mediated decreases in
adiposity were associated with increased caloric expenditure.

Previous studies demonstrated that ILC2s in WAT are decreased in mice fed a
HFD compared to lean controls (Molofsky et al., 2013) and that transfer of IL-25elicited ILC2s could decrease body weight and improve insulin sensitivity in HFDfed mice (Hams et al., 2013). ILC2s are known to produce the effector cytokines
IL-5 and IL-13 to promote eosinophil and AAMac responses, respectively, in
WAT (Molofsky et al., 2013), and both eosinophils and AAMacs are reported to
limit obesity (Chang et al., 2012; Odegaard et al., 2007; Odegaard et al., 2008;
Ricardo-Gonzalez et al., 2010; Wu et al., 2011). These studies provoke the
hypothesis that the function of ILC2s in WAT is to sustain eosinophils and
AAMacs to maintain optimal metabolic homeostasis.

Consistent with this,

treatment of mice with exogenous IL-33 is associated with increased ILC2,
eosinophil and AAMac frequencies and numbers in WAT and attenuated weight
gain in genetically obese ob/ob mice (Miller et al., 2010; Molofsky et al., 2013).
Further, IL-33R-deficient mice are reported to be more susceptible to dietinduced obesity compared to IL-33R-sufficient controls (Miller et al., 2010).
However, ILC2s have not been previously identified in human WAT, and the
endogenous factors that regulate ILC2s in WAT remain poorly characterized. In
this Chapter, we identify a lineage-negative CD25+ CD127+ GATA-3+ IL-33R+ cell
population in human WAT consistent with ILC2s identified in other human tissues
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(Bartemes et al., 2014; Hams et al., 2014; Kim et al., 2013; Kim et al., 2014;
Mjosberg et al., 2012; Mjosberg et al., 2011; Monticelli et al., 2011; Spits et al.,
2013; Xue et al., 2014), and demonstrate that obesity in both humans and mice
is associated with decreased ILC2 populations in WAT. Through loss-of-function
studies we also identify that IL-33 is necessary to maintain ILC2 responses and
limit the development of obesity. Collectively, these results indicate that the IL33/ILC2 axis is operational in the steady state to limit adiposity and suggest that
decreases in ILC2s in WAT in the context of obesity might be one factor that
contributes to weight gain.

IL-33 is highly expressed in white adipose tissue (Thorrez et al., 2008) and is
produced predominantly by adipocytes and endothelial cells (Zeyda et al., 2013).
Expression levels of IL-33 mRNA and protein are reported to be increased in
WAT of obese humans compared to non-obese controls and in HFD-fed mice
compared to LFD-mice (Zeyda et al., 2013). In serum, however, IL-33 levels in
sera of humans and mice appear to be unchanged (Zeyda et al., 2013) or
decreased (Hasan et al., 2014) in the context of obesity, suggesting that there
may be tissue-specific effects of obesity on IL-33 levels. Although increased IL33 levels in WAT would be expected to elicit WAT ILC2 responses, our
observation that ILC2s are decreased in obesity suggests that perhaps the IL33/ILC2 axis might be dysregulated in established obesity. Future studies to
address this topic are warranted.
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The data in this Chapter also indicate that administration of exogenous IL-33 can
elicit ILC2 responses in association with decreased adiposity and enhanced
glucose tolerance. These beneficial metabolic effects of the IL-33/ILC2 pathway
are consistent with previous studies showing a protective role for IL-33 in
genetically obese mice and may be related to obesity-associated pathologies
such as atherosclerosis that are limited by IL-33 (Hasan et al., 2014; Miller et al.,
2010; Miller et al., 2008). However, whether IL-33 has protective effects against
obesity through regulation of caloric expenditure or intake remains poorly
characterized. In this Chapter, we demonstrate that chronic IL-33 treatment is
associated with increased caloric expenditure but not decreased food intake.
Although increased metabolic rate would be expected to result in compensatory
increases in food intake to maintain energy balance, IL-33 did not have this
effect, apparently due to decreased activity levels and possibly other processes.
Importantly, these data suggest that IL-33 does not increase caloric expenditure
via the thermic effect of food or through increased activity levels, two important
factors that influence metabolic rate (Poehlman and Horton, 1989), and suggest
that other physiologic processes are responsible for the increased energy
expenditure following IL-33 treatment.

At steady state WAT contains a diverse set of type 2 cytokine-associated
immune cells that are critical for the maintenance of metabolic homeostasis
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(Gregor and Hotamisligil, 2011; Jin et al., 2013; Lumeng and Saltiel, 2011;
Odegaard and Chawla, 2011; Osborn and Olefsky, 2012). Emerging studies
suggest that ILC2s are a critical upstream mediator of the eosinophil/IL-4/AAMac
pathway in WAT that has been previously demonstrated to maintain metabolic
homeostasis and limit the development of obesity (Chang et al., 2012; Hams et
al., 2013; Molofsky et al., 2013; Odegaard et al., 2007; Qiu et al., 2014; RicardoGonzalez et al., 2010; Wu et al., 2011; Xu et al., 2013). The data in this Chapter
indicate that decreased ILC2s in WAT is a conserved feature of obesity in mice
and humans. In addition, we demonstrate that IL-33 is necessary and sufficient
to promote ILC2 responses in WAT and limit the development of obesity.

As

adipocytes are an important source of IL-33 in the context of increased weight
gain (Zeyda et al., 2013), the IL-33/ILC2 axis may represent one mechanism for
mammals to couple metabolic changes in adipose to innate immune pathways
that increase caloric expenditure. Dysregulation of the IL-33/ILC2 pathway may
therefore promote increases in adiposity. In addition, these findings suggest that
the IL-33/ILC2 axis might be a useful therapeutic target to treat obesity.
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2.6 Tables and Figures
Table 1. Characteristics of non-obese and obese human donors.
Non-obese

Obese

(n=7)

(n=7)

29/71

43/57

P=0.43

39.3 +/- 5.2

52.6 +/- 2.7

P=0.042

43

87

P=0.094

23.5 +/- 1.4

42.6 +/- 3.9

P=0.0006

History of Type 2 diabetes (%)

14

43

P=0.24

History of liver disease (%)

0

0

n/a

History of cardiovascular disease (%)

0

13

P=0.30

Characteristic
Source of tissue
(% CHTN/% NYODP)
Age
Sex, % female
BMI (kg/m2)

P-value*

BMI, body mass index; CHTN, Cooperative Human Tissue Network; NYODP,
New York Organ Donor Program
*Proportions were compared by X2 tests. Continuous variables were compared
by Student’s t-test. Exact P-values are shown.
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Figure 5. Identification of human Group 2 innate lymphoid cell (ILC2s)
in white adipose tissue (WAT). (a) Gating strategy to identify human
ILCs. Stromal vascular fraction (SVF) cells from human abdominal
subcutaneous WAT were isolated and subjected to flow cytometric
analyses. First plot pre-gated on singlets. Lineage cocktail 1 (Lin1): CD3,
CD5, TCRαβ. Lineage cocktail 2 (Lin2): CD19, CD56, CD11c, CD16. ILCs
are identified as Lin-negative cells that are CD25+ CD127+. Plots shown are
from an obese donor. (b) Identification of lineage (Lin)-negative CD25+
CD127+ innate lymphoid cells (ILCs) in human abdominal subcutaneous
WAT from a lean donor. Pre-gated on live CD45+ Lin− cells that lack CD3,
CD5, TCRαβ, CD19, CD56, CD11c, CD11b, CD16, and FcεRIα. (c)
Histograms of GATA-3 and IL-33R expression by human WAT ILCs (line).
Shaded histogram, isotype control. Gated on live CD45+ Lin− CD25+
CD127+ ILCs.
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Figure 6. Identification of murine Group 2 innate lymphoid cell
(ILC2s) in white adipose tissue (WAT). (a) Gating strategy to identify
murine ILCs. Stromal vascular fraction (SVF) cells from murine epididymal
(E)-WAT were isolated and subjected to flow cytometric analyses. First
plot pre-gated on singlet live cells. Lineage cocktail 1 (Lin1): CD3, CD5,
CD19, NK1.1. Lineage cocktail 2 (Lin2): CD19, CD11c. ILCs are identified
as Lin-negative cells that are CD25+ CD127+. (b) Phenotypic
characterization of ILCs from murine E-WAT. Left-hand plot shows
Identification of Lin− CD25+ CD127+ ILCs in murine epididymal (E)-WAT.
Pre-gated on live CD45+ Lin− cells that lack CD3, CD5, CD19, NK1.1,
CD11c, CD11b and FcεRIα. Right-hand plots are gated on live CD45+ Lin−
CD25+ CD127+ ILCs and show histograms of CD90, CCR6, GATA-3 and
IL-33R expression by murine E-WAT ILCs (line). Shaded histogram,
isotype control.
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Figure 7. Developmental and functional characteristics of murine
ILCs from epididymal white adipose tissue (E-WAT). (a-c) Stromal
vascular fraction (SVF) cells from murine E-WAT were isolated and
subjected to flow cytometric analyses. ILCs were defined as live CD45+
Lin− CD25+ CD127+ cells. The lineage (Lin) cocktail included CD3, CD5,
CD19, NK1.1, CD11c, CD11b and FcεRIα. Comparison of Lin− CD25+
CD127+ cells in E-WAT of (a) Id2+/+ versus Id2−/− bone marrow chimeras,
(b) Tcf7+/+ versus Tcf7−/− mice and (c) Rag2−/− versus Rag2−/− γc−/− mice.
N=3-8 mice per group from 2 independent experiments. (d) E-WAT SVF
cells from C57BL/6 mice were treated with PMA (100 ng/mL) and
ionomycin (1 µg/mL) in the presence of Brefeldin A (10 µg/mL) for 4h and
stained for ILCs. Live CD45+ Lin- CD25+ CD127+ IL-33R+ cells were pregated, and IL-5 and IL-13 protein levels were assessed. Plot shown is
representative of n=12 mice from 3 independent experiments.
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Figure 8. ILC2 populations in human white adipose tissue (WAT) are
decreased in obese patients. (a) Representative plots and (b) frequencies
of human WAT ILC2s from donors stratified into non-obese (body mass
index [BMI]<30.0 kg/m2, n=7) and obese (BMI≥30.0 kg/m2, n=7) groups.
Pre-gated on live CD45+ Lin− cells that lack CD3, CD5, TCRαβ, CD19,
CD56, CD11c, CD11b, CD16, and FcεRIα. Student’s t-test, *P<0.05. (c)
Frequencies of ILC2s are inversely correlated with BMI. Vertical dashed line
demarcates BMI = 30.0 kg/m2. Linear regression. Pearson correlation
moment (r) is of the best-fit line, which is shown on the graph. Exact P-value
shown. *P<0.05.
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Figure 9. ILC2 frequencies tend to be decreased in human white
adipose tissue (WAT) irrespective of source, and differences in ILC2
frequencies between sources are explained by body mass index
(BMI). (a) Frequencies of human ILC2s (Lin− CD25+ IL-33R+ cells) in
subcutaneous WAT of non-obese (BMI < 30.0 kg/m2) and obese (BMI ≥
30.0 kg/m2) donors stratified by source of tissue. Gated on live CD45+
Lin− CD25+ IL-33R+ cells. The lineage (Lin) cocktail included CD3, CD5,
TCRαβ, CD19, CD56, CD11c, CD11b, CD16, and FcεRIα. NYODN, New
York Organ Donor Network. CHTN, Cooperative Human Tissue NetworkEastern Division. (b) BMI of non-obese and obese donors stratified by
source of tissue. The horizontal dashed line demarcates the cut off of
non-obese vs obese donors. Non-obese from NYODN, n=4. Non-obese
from CHTN, n=3. Obese from NYODN, n=4. Obese from CHTN, n=3.
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Figure 10. Age and biological sex do not explain differences in WAT
ILC2 frequencies observed between non-obese and obese donors. (a)
Human WAT ILC2 frequencies were compared in the 7 youngest donors (36.0
+/- 3.5 years old) versus the 7 oldest donors (55.9 +/- 1.9 years old). (b)
Human WAT ILC2 frequencies in female non-obese donors with body mass
index (BMI) <30.0 kg/m2 versus female obese donors with BMI ≥30.0 kg/m2.
In both panels, ILC2s were defined as live CD45+ Lin− CD25+ IL-33R+ cells,
where the lineage (Lin) cocktail included CD3, CD5, TCRαβ, CD19, CD56,
CD11c, CD11b, CD16, and FcεRIα. Student’s t-test. **P<0.01, ***P<0.001.
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Figure 11. ILC2 populations are decreased in epididymal white
adipose tissue (E-WAT) of high fat diet (HFD)-induced obese mice.
(a) Representative plots and frequencies of murine E-WAT ILC2s from
mice fed a control diet (CD, 10% kcal fat, n=5) or high fat diet (HFD, 45%
kcal fat, n=4) for 12 weeks. (h) Numbers of murine ILC2s/gram E-WAT in
mice fed a CD (n=8) or HFD (n=6) for 12 weeks. Student’s t-test,
**P<0.01, ***P<0.001.
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Figure 12. IL-33-deficient mice exhibit decreased frequencies and
numbers of ILC2s in white adipose tissue (WAT). Il33+/+ (n=6) or Il33−/−
(n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks starting at 7
weeks of age. (a) Frequencies and numbers of live CD45+ Lin− CD25+ IL33R+ ILC2s in epididymal (E)-WAT. Plots pre-gated on CD45+ Lin− cells
that lack CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα. (b)
Frequencies and numbers of live CD45+ Lin− CD25+ IL-33R+ ILC2s in
inguinal (i)WAT. Plots pre-gated on CD45+ Lin− cells that lack CD3, CD5,
CD19, NK1.1, CD11c, CD11b and FcεRIα. Student’s t-test, *P<0.05,
**P<0.01.
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Figure 13. IL-33-deficient mice exhibit decreased frequencies and
numbers of ILC2s in white adipose tissue (WAT). Il33+/+ (n=6) or
Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks
starting at 7 weeks of age. Epididymal (E)-WAT and inguinal (i)WAT
SVF were treated with PMA (100 ng/mL) and ionomycin (1 µg/mL) in the
presence of Brefeldin A (10 µg/mL) for 4h prior to staining for ILC2s and
intracellular cytokines. Representative plots and frequencies of IL-5+ IL13− and IL-5+ IL-13+ ILC2s from E-WAT and iWAT are shown. Plots pregated on CD45+ Lin− CD25+ IL-33R+ ILC2s, where the lineage (Lin)
cocktail included CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα.
Student’s t-test, ***P<0.001.
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Figure 14.
IL-33-deficient mice gain more weight and exhibit
increased adiposity compared to IL-33-sufficient mice. Il33+/+ (n=6) or
Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12 weeks
starting at 7 weeks of age. (a) Absolute and (b) relative body weights over
the first 10 weeks of feeding. (c) Absolute and relative epididymal (E)WAT and inguinal (i)WAT weights. (d) iWAT sections were H&E stained
and imaged at 40X magnification. Adipocyte area was calculated from 2540 adipocytes total from 2-3 images per mouse. (e) Body composition
analyses. Student’s t-test or ANOVA with repeated measures. *P<0.05,
**P<0.01, ***P<0.001.
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Figure 15. IL-33-deficient mice exhibit impaired glucose homeostasis.
Il33+/+ (n=6) or Il33−/− (n=5) mice were fed a low fat diet (10% kcal fat) for 12
weeks starting at 7 weeks of age. On week 10, mice were fasted for 16 hours
followed by glucose tolerance testing (GTT). On week 11, mice were fasted
for 4-6 hours followed by insulin tolerance testing (ITT). (a) 16-hour fasting
blood glucose concentrations.
(b) 16-hour fasting serum insulin
concentrations. (c) Homeostatic model assessment of insulin resistance
(HOMA-IR) index values. (d) GTT with 2 g/kg glucose following a 16-hour
fast. (e) ITT with 0.5 U/kg insulin following a 5-hour fast. For panels a-c,
groups were compared using Student’s t-test, *P<0.05. For panels d-e, a
two-way ANOVA with repeated measures was performed followed by Tukey
post-hoc test. *P<0.05, **P<0.01, ***P<0.001. Data shown are from a single
cohort and are representative of 2 independent experiments.

70

Figure 16. IL-33 increases E-WAT ILC2s and abrogates the development
of obesity and glucose intolerance in mice fed a high fat diet (HFD). Male
C57BL/6 mice were placed on a control diet (CD) or HFD (60% kcal fat) at age
8 weeks. On the first day of feeding, CD mice were treated with PBS and HFD
mice were treated with PBS or recombinant murine (rm)IL-33 (12.5 µg/kg) once
every 4 days by intraperitoneal injection for 4 weeks. (a) E-WAT ILC2 numbers
per gram of adipose, (b) body weight, (c) relative E-WAT weight and (d) relative
iWAT weight at week 4. (e) 16-hour fasting blood glucose concentrations and
(f) glucose tolerance testing during week 3. All panels include n=10 mice per
group from 2 independent cohorts, except panel A which includes n=16 CD
PBS and n=18 HFD PBS from 4 independent cohorts. Panels a-e, One-way
ANOVA with Tukey post-hoc test,* P<0.05, **P<0.01, ***P<0.001. Panel f,
Two-way ANOVA with repeated measures, ***P<0.001 comparing CD PBS vs
HFD PBS, ^^^P<0.001 comparing HFD PBS vs HFD IL-33.
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Figure 17. Exogenous IL-33 promotes ILC2 responses in white adipose
tissue and limits adiposity in association with increased caloric
expenditure. Wildtype mice were treated with phosphate buffered saline
(PBS, n=10) or recombinant murine IL-33 (12.5 µg/kg/day, n=12) by
intraperitoneal injection for 7 days.
(a-b) Representative plots with
frequencies and numbers of ILC2s in (a) epididymal (E)-WAT and (b)
inguinal (i)WAT. (c) Body weight and (k) body composition. (l) Caloric
expenditure over a 24-hour period, days 6-to-7 of treatment. Non-shaded
area, lights on. Shaded area, lights off.
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Figure 18. Exogenous IL-33 treatment does not affect food intake, and
the absence of hyperphagia following IL-33 treatment may be due to
decreased activity levels. Wildtype mice were treated with phosphate
buffered saline (PBS, n=10) or recombinant murine IL-33 (12.5 µg/kg/day,
n=12) by intraperitoneal injection for 7 days. (a) Food intake and (b) total
activity levels (beam breaks) assessed by Comprehensive Laboratory Animal
Monitoring System (CLAMS) cages over a 24 hour period between days 6 and
7 of treatment. Student’s t-test, *P<0.05. (c) The average difference in food
intake or ambulatory activity (beam breaks) between PBS- and rmIL-33-treated
mice was calculated for each 15 min interval during the CLAMS cage analyses
in panels a-b, and the differences in food intake and ambulatory activity at each
time point were related by linear regression. Solid line, best-fit line. Dashed
curves, upper and lower 95% confidence intervals around the best-fit line.
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Chapter 3: The IL-33/ILC2 pathway promotes beiging of
white adipose tissue

3.1 Abstract
Obesity is an increasingly prevalent disease regulated by genetic and
environmental factors. Emerging studies indicate that immune cells, including
monocytes, granulocytes and lymphocytes, regulate metabolic homeostasis and
are dysregulated in obesity. Group 2 innate lymphoid cells (ILC2s) can regulate
adaptive immunity and eosinophil and alternatively-activated macrophage
responses, and were recently identified in murine white adipose tissue (WAT)
where they may act to limit the development of obesity6. In the previous Chapter,
we demonstrated that decreased ILC2 populations in WAT are a conserved
characteristic of obesity in humans and mice and that IL-33 is critical for
maintaining ILC2s in WAT and limiting adiposity in mice by increasing caloric
expenditure.

However the mechanisms by which IL-33 and ILC2s regulate
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metabolic homeostasis remain unknown. In this Chapter, we demonstrate that
IL-33 treatment is associated with recruitment of uncoupling protein 1 (UCP1)+
beige adipocytes in WAT, a process known as beiging or browning that regulates
caloric expenditure7-9.

IL-33-induced beiging appeared to be dependent on

ILC2s, and IL-33 treatment or transfer of IL-33-elicited ILC2s was sufficient to
drive beiging independently of the adaptive immune system, eosinophils or IL-4
receptor signaling.

We found that ILC2s produce methionine-enkephalin

peptides that can act directly on adipocytes to upregulate Ucp1 expression in
vitro and that promote beiging in vivo. Collectively, these studies indicate that in
addition to responding to infection or tissue damage, ILC2s can regulate adipose
function and metabolic homeostasis in part via production of enkephalin peptides
that elicit beiging.

3.2 Introduction
Three adipocyte cell types – white, brown and beige – are regulated by geneenvironment interactions to differentially control energy storage and expenditure
(Harms and Seale, 2013; Pfeifer and Hoffmann, 2014; Wu et al., 2013). White
adipocytes are found in white adipose tissues (WAT), store large amounts of
triglycerides (TG) and produce a variety of hormones such as leptin, adiponectin,
resistin and adipsin that regulate food intake and glucose homeostasis (Badoud
et al., 2014; Peirce et al., 2014; Pfeifer and Hoffmann, 2014). In contrast to white
adipocytes, brown adipocytes are found in discrete brown adipose tissue (BAT)
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depots, the largest of which is located in the interscapular space in mice, and
contain multiple small lipid droplets and abundant Uncoupling protein 1 (UCP1)+
mitochondria that uncouple fatty acid and glucose oxidation from ATP synthesis,
resulting in the production of heat (Cannon and Nedergaard, 2004; Harms and
Seale, 2013). This thermogenic process is dependent on UCP1 and is critical for
defending core body temperature and regulating metabolic rate and the
development of obesity(Carey et al., 2013; Cohen et al., 2014; Feldmann et al.,
2009; Harms and Seale, 2013; Rosen and Spiegelman, 2014; Saito et al., 2009;
Wu et al., 2012; Wu et al., 2013; Yoneshiro et al., 2011).

Recent studies have also identified a third adipocyte cell type, the beige
adipocyte (also known as brite, brown-like or inducible brown adipocyte) that is
dispersed within WAT but with morphologic and functional characteristics of
brown adipocytes (Bartelt and Heeren, 2014; Harms and Seale, 2013; Wu et al.,
2013).

These specialized adipocytes emerge in WAT in response to

environmental signals, a process known as beiging or browning, and also act to
produce heat in an UCP1-dependent manner(Harms and Seale, 2013; Rosen
and Spiegelman, 2014; Shabalina et al., 2013; Wu et al., 2012; Wu et al., 2013).
UCP1 is highly expressed in brown and beige but not white adipocytes (Wu et
al., 2012).

BAT in humans has been shown to contain adipocytes with

morphologic and gene expression signatures consistent with beige rather than
brown adipocytes (Jespersen et al., 2013; Sharp et al., 2012; Wu et al., 2012).
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Activation of these beige/brown fat depots is defective in obese humans (Carey
et al., 2013; Saito et al., 2009), and recent studies indicate that selective deletion
of beige adipocytes while leaving BAT intact increases susceptibility to obesity in
mice (Cohen et al., 2014).

Therefore beige adipocytes appear to be critical

mediators of energy homeostasis.

Although a variety of factors have been shown to activate both brown and beige
adipocytes (Harms and Seale, 2013; Rosen and Spiegelman, 2014; Wu et al.,
2013), recent studies suggest that type 2 cytokine-associated immune cells such
as eosinophils and alternatively activated macrophages (AAMacs) are necessary
for optimal brown and beige adipocyte responses (Nguyen et al., 2011; Qiu et al.,
2014; Rao et al., 2014). Mice that lack IL-4 and IL-13 (Il4/13−/−); the shared
receptor for these cytokines, IL-4Rα (Il4ra−/−); or STAT6, a transcription
downstream of IL-4Rα signaling (Stat6−/−) have defective AAMac responses
(Martinez et al., 2009) and exhibit decreased upregulation of UCP1 expression in
BAT and impaired defense of core body temperature following acute exposure to
cold environmental temperatures (Nguyen et al., 2011).

IL-4 was shown to

activate AAMacs to produce catecholamines such as norepinephrine (NE) that
act on the β3 adrenergic receptor (β3AR) to stimulate lipolysis, elicit mitochondrial
biogenesis and activate UCP1 in BAT (Nguyen et al., 2011). However IL-4/IL4Rα interactions do not appear to be required for BAT responses in the context
of chronic exposure to severe cold environmental temperatures over a period of
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3 days (Qui et al., 2014). In this context, eosinophils are recruited to WAT and
produce IL-4 to stimulate AAMac production of NE to promote beiging of WAT
(Qiu et al., 2014; Rao et al., 2014). Mice lacking eosinophils, IL-4Rα or STAT6
failed to undergo optimal beiging of WAT and had decreased metabolic rate
compared to wildtype controls in the setting of chronic cold exposure (Qiu et al.,
2014; Rao et al., 2014). Thus, the eosinophil/IL-4/AAMac/NE pathway appears
to have a critical role in the elicitation of both brown and beige adipocyte
responses and in the regulation of metabolic rate.

Group 2 innate lymphoid cells (ILC2s) are a recently described innate immune
cell that is a dominant source of IL-5 and IL-13 in WAT to promote eosinophil and
AAMac responses, respectively (Molofsky et al., 2013; Moro et al., 2010; Neill et
al., 2010; Nussbaum et al., 2013; Price et al., 2010). ILC2s have been previously
demonstrated to be decreased in WAT of obese mice (Molofsky et al., 2013) and
limit the development of obesity (Hams et al., 2013). However the mechanisms
by which ILC2s regulate metabolic homeostasis in WAT remain poorly
understood. In the previous Chapter, we demonstrated that decreased ILC2s in
WAT is a conserved characteristic of obesity in mice and humans, and that IL-33
is critical for promoting ILC2 responses and decreasing adiposity by increasing
caloric expenditure. Collectively, these findings provoke the hypothesis that the
IL-33/ILC2 axis might contribute to the regulation of caloric expenditure by
promoting the activation of brown and/or beige adipocytes.
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In this Chapter, we demonstrate that IL-33 treatment elicits beiging of WAT but
does not stimulate expression of Ucp1 in BAT, suggesting that IL-33 has
selective effects on beiging. IL-33-induced beiging appeared to be dependent on
ILC2s, and adoptive transfer of IL-33-elicited ILC2s was sufficient to drive beiging
of WAT and to increase inguinal (i)WAT oxygen consumption. Surprisingly, IL-33
and ILC2 transfer could elicit beiging in the absence of eosinophils and IL-4Rαdependent AAMacs, suggesting that the IL-33/ILC2 axis can promote beiging via
another mechanism. Gene expression analyses of 69 genes previously linked to
the development of obesity in humans revealed that ILC2s produce the
neuropeptide methionine-enkephalin (MetEnk). We show that MetEnk treatment
is sufficient to drive beiging of WAT in vivo and can act directly on primary
adipocytes from iWAT but not BAT to upregulate Ucp1 expression. Collectively,
these data indicate that the IL-33/ILC2 axis elicits beiging via production of
MetEnk peptides.

3.3 Methods
3.3.1 Mice
C57BL/6, CD45.1+ C57BL/6, Rag1−/− and DblGata1 (Balb/c background) mice
were obtained from Jackson Labs. Rag2−/−, Rag2−/− cy−/−, Il33+/+, Balb/c and
Il4ra−/− (Balb/c background) mice were obtained from Taconic. Il33−/− mice were
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provided by Amgen Inc via Taconic. All mice were males and had ad libitum
access to food and water and were maintained in a specific pathogen free facility
with a 12h:12h light:dark cycle (lights on at 7:00 AM, lights off at 7:00 PM).
Animals were randomly assigned to groups of n=3-5 mice per group per
experiment, and at least two independent experiments were performed
throughout. In all in vivo experiments, a single technical replicate per mouse was
performed. For all in vitro experiments, 2-3 technical replicates were performed
in each independent experiment. Sample sizes in each independent experiment
were selected to have power of at least 90% using published sample size/power
formulas (Brestoff and Van den Broeck, 2013). All experiments were carried out
under the guidelines of the Institutional Animal Care and Use Committee at the
University of Pennsylvania.

3.3.2 Rodent chow and diet-induced obesity
In all experiments, mice had ad libitum access to food and water. Where
indicated, mice were fed a control diet (CD, 10% kcal fat, Research Diets, New
Brunswick, New Jersey) for the indicated period of time starting at 6-8 weeks of
age.

CD was gamma-irradiated (10-20 kGy) and stored at 4 °C under dry

conditions until use, and rodents were provided fresh chow weekly.

In all

experiments that did not employ CD, mice were fed a standard autoclavable
rodent chow (5% kcal fat, #5010, Lab Diets, St. Louis, Missouri) that had been
autoclaved and allowed to cool overnight before use.
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3.3.3 In vivo cytokine and enkephalin peptide treatments.
Mice were administered 12.5 µg/kg carrier-free recombinant murine IL-33 (rmIL33, R&D Systems, Minneapolis, Minnesota) in sterile phosphate buffered saline
(PBS) by intraperitoneal (i.p.) injection daily for the indicated number of days. In
some studies, mice were treated with a previously reported dose (Zagon et al.,
2010) of 10 mg/kg [Met5]-enkephalin acetate salt hydrate (MetEnk, amino acid
sequence YGGFM, ≥95.0% purity by HPLC, Sigma Aldrich, St. Louis, MO) in
PBS or with PBS alone by bilateral subcutaneous injection near the iWAT daily
for 5 days (approximately 200 µL per side). MetEnk or vehicle injections were
performed under 2% isoflurane anesthesia. All injections were performed
between the hours of 4:00 PM and 7:00 PM.

3.3.4. Tissue oxygen consumption
A ~20 mg biopsy of iWAT was isolated from directly below the lymph node and
minced in PBS containing 2% BSA, 1.1 mM sodium pyruvate and 25 mM
glucose. Samples were placed in an MT200A Respirometer Cell (Strathkelvin),
and oxygen consumption was measured for approximately 5 min. Oxygen
consumption rates were normalized to minced tissue weight.
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3.3.5 Isolation of immune cells from adipose
Murine epididymal white adipose tissue (E-WAT), inguinal WAT (iWAT) or brown
adipose tissue (BAT) or human subcutaneous abdominal WAT were harvested
and dissected so as to be free of reproductive tissues, lymph nodes and fibrous
connective tissue. Tissues were finely minced using sterile scissors to form a
slurry that was subsequently digested with 0.1% collagenase type II (SigmaAldrich, USA) in high glucose DMEM at 37°C with shaking at 200 rpm for 60-90
min at a 45° angle. Digested tissues were filtered through a 70 µm nylon mesh.
The mesh was washed with approximately 20 mL Wash Media (high glucose
DMEM supplemented with 5% heat-inactivated fetal bovine serum [FBS], 100
units/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine). All Wash
Media reagents were from Life Technologies (Grand Island, NY) except FBS,
which was from Denville USA. Washed cells were centrifuged at 500 x g for 5
min at 4 °C, and then floating adipocytes were removed by aspiration and the
stromal vascular fraction (SVF) pellet was resuspended in red blood cell lysis
buffer (ACK RBC Lysis Buffer) and allowed to incubate at room temperature for 2
min. The RBC Lysis reaction was stopped by addition of 10 volumes Wash
Media, and the SVF cells were recovered by centrifugation at 500 x g for 5 min at
4 °C. Cells were resuspended in 200 µL Wash Media and aliquotted in equal
parts for immediate flow cytometric analysis or for re-stimulation as described
below for subsequent intracellular cytokine analysis by flow cytometry. In some
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experiments, all recovered SVF cells were used for immediate flow cytometric
analyses.

3.3.6

Surface and nuclear staining of murine cells for flow cytometric

analyses
Isolated SVF cells from mice were resuspended in 100 µL FACS PBS (sterile 1X
phosphate buffered saline [Invitrogen] supplemented with 2% heat-inactivated
FBS and 1 mM EDTA [Invitrogen] containing LIVE/DEAD Fixable Aqua Dead Cell
Stain (1:600) and anti-mouse IL-33R-biotin (T1/S2, clone DJ8) from MD
Bioproducts (St. Paul, MN) (1:300). Cells were incubated on ice for 30 min in the
dark and were washed twice in 250 µL FACS PBS with centrifugation at 500 x g
for 5 min at 4 °C before each wash.

Washed cells were stained with

combinations of the following antibodies (all of which were used at 1:300 dilutions
unless otherwise noted) in a volume of 90 µL staining buffer (FACS PBS
supplemented with 20 µg/mL rat IgG): anti-mouse CD45-eFluor 605NC (clone
30-F11; 1:200), CD45.1-eFluor 450 (A20; 1:100), CD45.2-AlexaFluor 700 (104),
F4/80-eFluor 450 (BM8), CD3e-PerCP-Cy5.5 (145-2C11), CD5-PerCP-Cy5.5
(53-7.3), CD19-PerCP-Cy5.5 (1D3), NK1.1-PerCP-Cy5.5 (PK136), CD11cPerCP-Cy5.5 (N418), FcεRIα-FITC (MAR-1), Foxp3-FITC (FJK-16s; 1:100),
GATA-3-PE (TWAJ; 1:100) and CD25-PE-Cy7 (clone PC61.5) from eBioscience
(San

Diego,

CA);

CD11b-PE-Texas

Red

(M1/70.15;

1:500)

from

Life

Technologies (Grand Island, NY); CD90.2-Alexa Fluor 700 (30-H12; 1:400) and
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CD4-Brilliant Violet-650 (RM4-5) from BioLegend (San Diego, CA); SiglecF-PE
(E50-2440) and CD3e-PE-CF594 (145-2C11) from BD Biosciences (San Jose,
CA); CD206-Alexa Fluor 647 (MR5D3; 1:200) from AbD Serotec (Raleigh, NC);
and Streptavidin-APC (1:300) from eBioscience. CD206 staining was performed
following fixation and permeabilization with the Foxp3 Staining Buffer Set
(eBioscience) according to the manufacturer’s protocol. All intracellular stains
were performed in 1X Permeabilization Buffer (PB, eBioscience) for 45 min on
ice. Cells were washed 3 times in 250 µL 1X PB with centrifugation at 500 x g for
5 minutes at 4 °C between washes, and recovered cells were resuspended in
200 µL FACS Buffer before flow cytometric analyses.

3.3.7 Intracellular cytokine analysis
To examine ILC2 MetEnk production, ILC2s were sort-purified from E-WAT of IL33-treated mice, as described below. Ten thousand ILC2s were re-stimulated for
4 days with rmIL-2 (10 ng/ml) and rmIL-7 (10 ng/mL) in the presence or absence
of rmIL-33 (30 ng/mL) in complete media (Wash Media with 10% FBS, 55 µM 2mercaptoethanol and 25 mM HEPES) at 37 °C with 5% CO2. All cytokines were
from R&D Systems (Minneapolis, Minnesota).

During the final 4 hours of

treatment, cells were treated with Brefeldin A (10 µg/mL) (Sigma-Aldrich) and
monensin (1:1500) in a 37°C incubator (5% CO2).

Cells were then surface

stained and fixed/permeabilized using Cyto Fix/Perm (BD Pharmingen) according
to manufacturer’s instructions before intracellular staining with rabbit anti-mouse
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MetEnk (bs-1759R, Bioss USA, Woburn, MA; 1:200) or rabbit anti-mouse IgG
(Isotype control, Bioss USA; 1:200) followed by staining with goat anti-rabbit PE
(sc-3739, 1:400; Santa Cruz Biotechnology, Dallas, TX). All intracellular stains
were performed in 1X Permeabilization Buffer (PB, eBioscience) for 45 min on
ice. After each intracellular stain, cells were washed 3 times in 250 µL 1X PB
with centrifugation at 500 x g for 5 minutes at 4 °C between washes. Recovered
cells after the final wash were resuspended in 200 µL FACS Buffer before flow
cytometric analyses.

3.3.8 Flow cytometry
For all flow cytometry analyses, stained cells were acquired on a BD LSRII flow
cytometer (BD Biosciences). The entirety of each sample was acquired to obtain
total cell counts, which were subsequently normalized to tissue weight. Flow
cytometry data were analyzed using FlowJo software version 9.6.4 (Tree Star,
Inc.).

3.3.9 Sort-purification and transfer of ILC2s
E-WAT was harvested from male CD45.1+ C57BL/6 mice that received daily
injections of rmIL-33 (12.5 µg/kg) for 7 days by intraperitoneal injection. The
stromal vascular fraction (SVF) was isolated as described above, and Live
CD45+ Lin− CD25+ IL-33R+ ILC2s were sort-purified using an Aria Cell Sorter
(BD) to ≥98% purity. The lineage cocktail for sorts included CD3, CD5, CD19,
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NK1.1, CD11c, CD11b, FcεERIα and SiglecF. CD45.1+ ILC2s (105) were
immediately transferred to the indicated recipient mice by intraperitoneal injection
(5 x 104 cells) and by subcutaneous injection near iWAT (5 x 104 cells split evenly
for bilateral injections). Daily transfers were performed for 4 consecutive days,
and tissues were harvested on day 5.

In ILC2 reconstitution experiments

involving Rag2−/− γc−/− recipient mice, 105 CD45.1+ ILC2s were transferred by a
single intraperitoneal injection, and the next day mice were treated with PBS or
rmIL-33 (12.5 µg/kg) by daily intraperitoneal injection for 7 days. In ILC2 transfer
experiments involving recipient mice on a Balb/c background (DblGata1 or
Il4ra−/−), donor ILC2s were sort-purified as described above from E-WAT of
Balb/c mice that received daily injections of rmIL-33 (12.5 µg/kg) daily for 5-7
days by intraperitoneal injection.

Balb/c ILC2s (105) were immediately

transferred to the indicated recipient mice by intraperitoneal injection (5 x 104
cells) and by subcutaneous injection near iWAT (5 x 104 cells split evenly for
bilateral injections). Daily transfers were performed for 4 consecutive days, and
tissues were harvested on day 5.

3.3.10 Histologic analysis
Tissues were fixed in 4% paraformaldehyde in PBS for at least 48 hours at 4°C
and embedded in paraffin before cutting 5 µm sections and staining with
hematoxylin and eosin (H&E) or performing immunohistochemistry (IHC) with
rabbit anti-UCP1 antibody (Abcam, ab10983).
86

For IHC, rehydrated sections

were microwaved in 10 mM citric acid buffer (pH 6.0) for antigen retrieval, and
endogenous peroxidases were quenched with 3% hydrogen peroxide. Sections
were blocked with Avidin D, biotin and protein blocking agent in sequential order
followed by application of the anti-UCP1 antibody (1:500). A biotinylated antirabbit antibody was used as a secondary antibody. Horseradish peroxidaseconjugated ABC reagent was applied, and then DAB reagent was used to
develop the signal before counterstaining in hematoxylin and dehydrating the
sections in preparation for mounting. Stained sections were visualized and
photographed using a Nikon E600 brightfield microscope.

3.3.11 Real-time PCR
Adipose tissues were snap-frozen in 1.0 mL TRIzol (Invitrogen) and
homogenized using a Tissue Lyser (Qiagen) with a 5mm RNase-free metal bead
(Qiagen).

Homogenates were centrifuged at 10,000 x g for 15 min at room

temperature, and 700 µL of the TRIzol interphase was collected to exclude the
top lipid phase and cellular debris and genomic DNA in the pellet. Chloroform
(200 µL; Fisher Scientific) was added to the lipid-extracted TRIzol fraction and
shaken vigorously for 15 seconds before benchtop incubation at room
temperature for 2-3 min. Samples were centrifuged at 10,000 x g for 15 min at
room temperature, and the top aqueous phase was collected (250 µL) into tubes
containing 500 µL isopropanol (Sigma Aldrich) to precipitate the RNA. Samples
were mixed gently by vortexing on setting 4 (of 10) for 3-5 seconds and allowed
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to incubate at room temperature for 10 min.

Samples were then applied to

RNeasy Mini columns (Qiagen), and RNA was purified and isolated in
accordance with the manufacturer’s instructions.

Purified total RNA samples

were eluted in 30-50 µL RNase-free water (Qiagen), and total RNA
concentrations were determined using a Nanodrop 2000c (Thermo Scientific,
Wilmington, DE).

cDNA was synthesized in 20 µL reactions from 1.0 µg aliquots of RNA using
Superscript II Reverse Transcriptase (Invitrogen) and oligo(dT) (Invitrogen)
according to manufacturer’s instructions. cDNA was diluted with 180 µL
nuclease-free water (Promega) before used.

Real-time PCR was performed

using 10 µL reactions consisting of 5 µL Power SYBR Green 2X Master Mix
(Applied Biosystems), 3 µL nuclease-free water (Promega or Qiagen), 1 µL
diluted cDNA and 1 µL primers (1 µM). Previously published primer sequences
for murine Ucp117 and Qiagen Quantitect real-time PCR primers for β-actin, Il33,
Penk, Oprd1 and Ogfr. Reactions were performed in duplicate or triplicate using
the 7500 Fast Real-Time PCR System (Applied Biosystems) or the QuantStudio
6 Flex Real-Time PCR System (Applied Biosystems).

CT values were

normalized to the endogenous housekeeping gene β-actin. The ΔΔCT method
was employed for all real-time PCR analyses with expression levels for each
sample expressed relative to the average gene expression level of the indicated
control group.
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3.3.12 Microarrays and ILC2 vs ILC3 gene enrichment analyses
Microarray analyses (~25,000 genes) were performed using previously published
microarray datasets (GEO GSE46468) (Monticelli et al., 2011).

In brief, Lin-

CD90+ CD25+ IL-33R+ ILC2s from the lung (4 biological replicates each
comprising 6 pooled lungs) and Lin- CD90+ CD25+ CD4+ ILC3s from the spleen
(4 biological replicates each comprising 10 pooled spleens) were sorted using a
FACS Aria (BD) directly into TRIzol LS (Invitrogen) at a purity of >97% (1.5-2.0 x
104 cells/replicate). mRNA was isolated, amplified, labeled and hybridized to
Affymetrix GeneChip (Mouse Gene 1.0 ST) as described previously (Monticelli et
al., 2011). Gene expression Z-scores were calculated for each of 69 obesityassociated genes in ILC2s or ILC3s (see Table 2 for a complete list of genes).
First, the average and standard deviation of all microarray probe intensities were
calculated for each cell type.

The average probe intensity of the array was

subtracted from average probe intensity of each of the 69 obesity-associated
genes. The difference in average probe intensities (single gene minus array)
was divided by the array standard deviation to calculate the Z-score. Genes that
were significantly enriched compared to the average gene expression level of the
entire microarray dataset in one cell population but not the other (Z > +2.20) were
considered to be differentially enriched in that cell population. The Bonferroni
correction was used to determine the level of significance with 69 comparisons to
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account for multiple testing (α=0.05; k=69). The Bonferroni-corrected P-value for
level of significance was P = 0.014, which corresponds to a Z-score of ±2.20.

3.3.13 Primary adipocyte culture
iWAT or BAT was dissected from 4 week-old C57BL/6 mice (n=5 per experiment,
pooled) and digested as described above. Stromal vascular fraction (SVF) cells
were plated in 12-well CellBind plates, and adherent cells were grown to
confluence. Cells were differentiated into adipocytes as previously described
(Seale et al., 2011). Briefly, cells were cultured for 2 days with 850 nM insulin, 1
nM T3, 1 µM rosiglitazone, 125 nM indomethacin (125 µM for BAT primary
adipocytes), 0.5 mM isobutylmethylxanthine (IBMX) and 1 µM dexamethasone in
adipocyte culture media (DMEM:F12 [50:50] supplemented with 10% heatinactivated FBS, penicillin, streptomycin and L-glutamine). Cells were then
maintained in adipocyte culture media supplemented with 850 nM insulin and 1
nM T3 with either PBS or 50 µM MetEnk for 6 days, with fresh media
replacement every 2 days. Cells were harvested on day 8 in TRIzol.

3.3.14 Statistical analyses
All data are expressed as mean ± standard error of the mean (SEM), except
some human subject data that are expressed as proportions.

Statistical

significance was determined using the two-tailed Student’s t test or a one-way or
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two-way analysis of variance (ANOVA) followed by Sidak or Tukey post-hoc
tests. If variance differed between groups, the appropriate statistical correction
was applies (e.g. Welch’s correction).

Correlation analyses were conducted

using Pearson linear regression. Proportions among human samples were
compared by χ2 tests. Significance was set at P<0.05 except for microarray
analyses, in which case the Bonferroni correction was applied to account for
multiple testing (α=0.05, k=69), resulting in a level of significance of P<0.014.
Statistical analyses were performed with Prism 6 (GraphPad Software, Inc.) or
SPSS Statistics version 22 (IBM).

3.4 Results
3.4.1 IL-33 regulates beiging of white adipose tissue
Given the thermogenic properties of beige and brown adipocytes (Harms and
Seale, 2013; Pfeifer and Hoffmann, 2014; Rosen and Spiegelman, 2014; Wu et
al., 2013), we tested whether IL-33 treatment regulates the morphology or Ucp1
expression levels in WAT and BAT. In PBS-treated controls, E-WAT and iWAT
from PBS-treated mice exhibited predominantly unilocular white adipocytes, and
iWAT had interspersed paucilocular beige adipocytes that are characterized
morphologically by multiple small lipid droplets and increased UCP1+ cytoplasm
(Fig 19a). Mice receiving rmIL-33 exhibited increased UCP1+ beige adipocytes
in E-WAT and iWAT compared to PBS-treated controls (Fig. 19a). In addition,
expression levels of Ucp1 in E-WAT and iWAT were significantly increased in
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mice treated with rmIL-33 compared to controls (Fig. 19b).
suggest that IL-33 can promote beiging of WAT.

These results

rmIL-33 also resulted in

increased frequencies (Fig. 20a) and numbers (Fig. 20b) of Lin− CD25+ IL-33R+
ILC2s in BAT. However, in contrast to WAT, BAT from rmIL-33-treated mice
exhibited decreased Ucp1 expression (Fig. 20c) without apparent morphologic
changes to brown adipocytes (Fig. 20d,e). Taken together, these results indicate
that the stimulatory effect of rmIL-33 treatment on UCP1 expression was
selective to WAT but not BAT.

To further test whether IL-33 regulates beiging, we examined WAT morphology
and Ucp1 expression levels of Il33+/+ versus Il33−/− mice that had been fed a 10%
fat diet for 12 weeks. iWAT from Il33+/+ mice was predominantly comprised of
white adipocytes with interspersed UCP1+ beige adipocytes (Fig. 21a), whereas
iWAT from Il33−/− mice had few beige adipocytes (Fig. 21b). Consistent with this,
Ucp1 expression was significantly lower in iWAT of Il33−/− mice compared to
Il33+/+ controls (Fig. 21c). These findings indicate that endogenous IL-33 is a
critical regulator of beiging.

3.4.2 IL-33-elicited ILC2s are sufficient to drive beiging of white adipose
tissue
To test whether IL-33-elicited ILC2s can promote beiging, congenically marked
CD45.1+ ILC2s from E-WAT of IL-33-treated donor mice were sort-purified and
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adoptively transferred into wildtype CD45.2+ recipient mice (Fig. 22a). CD45.1+
donor ILC2s could be identified in iWAT of mice that received ILC2s but not
control mice that received PBS (Fig. 22b), and total ILC2 numbers were
significantly increased in iWAT of mice receiving CD45.1+ ILC2s compared to
controls (Fig. 22c). Transferred ILC2s could also be identified in E-WAT but
were not found in BAT, mesenteric lymph nodes or lung (Fig. 23), demonstrating
selective accumulation of WAT-derived ILC2s in WAT of recipient mice. Mice
that received ILC2s had increased UCP1+ beige adipocytes (Fig. 22d) and
augmented expression of Ucp1 (Fig. 22e) in iWAT compared to controls. In
addition, iWAT from mice that received ILC2s had elevated oxygen consumption
(Fig. 22f) in iWAT. Collectively, these results indicate that activated ILC2s can
promote beiging in wildtype mice.

ILC2s have been shown to regulate both T and B cell responses (Halim et al.,
2014; Mirchandani et al., 2014; Moro et al., 2010; Oliphant et al., 2014), and IL33 treatment is associated with increased regulatory T cells (Treg) responses in
mice (Schiering et al., 2014), a cell population previously implicated in regulation
of metabolic homeostasis in obese mice (Cipolletta et al., 2012; Zhong et al.,
2014) (Feuerer et al., 2009). Therefore we sought to test whether transferring IL33-elicited ILC2s could promote beiging in the absence of an adaptive immune
system. CD45.1+ donor ILC2s could be identified in iWAT of CD45.2+ Rag1−/−
recipients that received ILC2s (Fig. 24a), and this was associated with increased
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ILC2 numbers in iWAT compared to controls (Fig. 24b).

Similar to wildtype

recipients, Rag1−/− hosts demonstrated increased UCP1+ beige adipocytes (Fig.
24c) and upregulated expression of Ucp1 in iWAT (Fig. 24d) following ILC2
transfer. These data indicate that IL-33-elicited ILC2s are sufficient to promote
beiging in the absence of the adaptive immune system.

3.4.3 IL-33 may promote beiging in an ILC2-dependent manner
The findings that IL-33 treatment and ILC2 transfer could promote beiging of
WAT provoked the hypothesis IL-33 promotes beiging in an ILC2-dependent
manner. To test this, we first sort-purified ILC2s from IL-33-treated CD45.1+
mice and reconstituted Rag2−/− γc−/− mice with ILC2s by a single adoptive
transfer by intraperitoneal injection. The next day, ILC2-sufficient Rag2−/− mice,
ILC2-deficient Rag2−/− γc−/− mice and ILC2-reconstituted Rag2−/− γc−/− mice were
treated with PBS or rmIL-33 daily for 7 days (Fig. 25a).

Following IL-33

treatment, ILC2-sufficient Rag2−/− control mice but not ILC2-deficient Rag2−/−
γc−/− mice demonstrated population expansion of E-WAT ILC2s (Fig. 25b,c).
Furthermore, Rag2−/− γc−/− mice supported accumulation and IL-33-induced
population expansion of donor ILC2s in host E-WAT (Fig. 25b,c). IL-33 treatment
increased expression of Ucp1 in E-WAT of ILC2-sufficient Rag2−/− mice but not
ILC2-deficient Rag2−/− γc−/− mice treated with rmIL-33 (Fig. 25d). Strikingly, IL33-induced increases in expression of Ucp1 and beiging were restored in ILC2reconstituted Rag2−/− γc−/− mice (Fig. 25d,e). Collectively, these results indicate
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that IL-33-induced beiging of WAT requires a γc-dependent cell population and
that ILC2s are sufficient to rescue this defect, suggesting that IL-33-induced
beiging is critically dependent on ILC2s.

3.4.4 IL-33 and ILC2s can elicit beiging independently of eosinophils and
the IL-4 receptor
In addition to regulating adaptive immune cell responses, ILC2s are known to
promote eosinophil and alternatively-activated macrophage (AAMac) responses
in multiple tissue compartments including WAT(Molofsky et al., 2013; Wu et al.,
2011). Recent studies indicate that eosinophils and IL-4Rα-dependent AAMac
responses are critical for beiging in the context of chronic exposure to cold
environmental temperatures (Qiu et al., 2014). We therefore tested whether IL33 or ILC2s could elicit beiging of WAT independently of eosinophils or IL-4Rα.
At steady state, UCP1+ beige adipocytes could be identified in iWAT of Balb/c
(wildtype), DblGata1 mice (that lack eosinophils) and Il4ra−/− mice (that have
dysregulated AAMac responses), and rmIL-33 treatment was associated with
elevated ILC2 responses in iWAT and increased UCP1+ beige adipocytes in
each of these strains (Fig. 26a-f). Further, adoptive transfer of IL-33-elicited
ILC2s was sufficient to promote beiging in DblGata1 and Il4ra-/- mice (Fig. 27a-d).
Eosinophils are reported to be increased in iWAT from mice exposed to cold
environmental conditions (Qiu et al., 2014; Rao et al., 2014), and ILC2s control
eosinophils responses in multiple tissues including WAT (Molofsky et al., 2013;
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Nussbaum et al., 2013).

However, exposure of C57BL/6 mice to 4 °C

temperatures for 72 hours resulted in upregulation of Ucp1 expression (Fig. 28a)
without altering the numbers of ILC2s (Fig. 28b) or expression of Il33 (Fig. 28c) in
iWAT or BAT. Thus, while eosinophils and AAMacs may contribute to optimal
beiging under some physiologic settings such as chronic exposure to severe cold
environmental temperatures (Qiu et al., 2014; Rao et al., 2014), these data
indicate that the IL33/ILC2 axis can promote beiging independently of the
eosinophil/IL-4Rα/AAMac pathway and may be associated with beiging in other
physiologic contexts.

3.4.5 ILC2s express methionine-enkephalin peptides that are upregulated
by IL-33 treatment
Obesity is associated with both decreased ILC2s (Chapter 2) and defective beige
adipocytes (Carey et al., 2013; Cohen et al., 2014; Molofsky et al., 2013; Saito et
al., 2009). To address whether ILC2s produce obesity-associated factors that
could regulate beiging, we employed genome-wide transcriptional profiling of
ILC2s versus group 3 ILCs (ILC3s), a related innate immune cell population
(Constantinides et al., 2014; Diefenbach et al., 2014; Monticelli et al., 2012; Spits
and Cupedo, 2012), to compare gene expression enrichment scores of 69 genes
previously linked to human obesity (Fig. 29a and Table 2) (McCarthy, 2010;
Walley et al., 2009).

This analysis identified that one gene, proprotein

convertase subtilisin/kexin type 1 (Pcsk1) (also known as prohormone
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convertase 1 [Pc1]), was significantly enriched in ILC2s but not ILC3s (Fig. 29b,
P<0.01). PCSK1 is an endopeptidase involved in processing some prohormones
into active forms (Seidah, 2011; Seidah et al., 2013), and loss-of-function
mutations in both mice and humans are associated with increased susceptibility
to obesity (Benzinou et al., 2008; Creemers et al., 2012; Lloyd et al., 2006) in
association with decreased caloric expenditure (Lloyd et al., 2006).

Of the

prohormones known to be processed by PCSK1, the most differentially
expressed in ILC2s compared to ILC3s was Proenkephalin A (Penk) (Fig. 29c),
which encodes endogenous opioid-like peptides such as methionine-enkephalin
(MetEnk, also known as opioid growth factor [OGF]). Production of MetEnk by
ILC2s was confirmed by flow cytometric analysis of sort-purified ILC2s restimulated with IL-2 and IL-7 (Fig. 29d). Following IL-33 stimulation of sortpurified ILC2s, production of MetEnk peptides on a per-cell basis was increased
(Fig. 29e).

Together, these findings demonstrate that ILC2s express

Proenkephalin A and its processing machinery to produce enkephalin peptides.

3.4.6

Methionine-enkephalin appears to have tissue-specific effects on

white versus brown adipose tissue
Tissue-level gene expression analyses in wildtype mice at steady state indicated
that Il33 and Penk expression levels were increased in iWAT compared to BAT
(Fig. 30a), and Il33 and Penk expression levels were correlated in iWAT but not
BAT of naïve C57BL/6 mice (Fig. 30b). In addition, expression of the MetEnk
97

receptor δ1 opioid receptor (Oprd1) was higher in iWAT compared to BAT,
whereas expression of the other known MetEnk receptor opioid growth factor
receptor (Ogfr) was lower in iWAT compared to BAT (Fig. 30c). Together, these
gene expression analyses suggest that there may be tissue-specific regulation of
the IL-33/PENK/MetEnk receptor pathways in iWAT compared to BAT. These
data also suggest that there might be tissue-specific of effects of MetEnk in iWAT
compared to BAT. Consistent with this, MetEnk stimulation of cultured primary
adipocytes from iWAT (Fig. 31a), but not cultured primary adipocytes from BAT
(Fig. 31b), induced Ucp1 expression.

This suggests that MetEnk has a

stimulatory effect on the expression of Ucp1 in adipocytes from iWAT but not
BAT.

3.4.7 Methionine-enkephalin administration is associated with increased
beiging of white adipose tissue in vivo
To test whether MetEnk can promote beiging in in vivo, MetEnk peptides (amino
acid sequence YGGFM) were delivered by subcutaneous injection into wild-type
mice. MetEnk treatment was associated with elicitation of UCP1+ beige (Fig.
32a) and upregulated expression of Ucp1 in iWAT (Fig. 32b). These changes
were associated with increased iWAT oxygen consumption (Fig. 32c), collectively
indicating the formation of functional beige fat.

Consistent with this, MetEnk

treatment was also associated with decreased iWAT mass (Fig. 32d). These
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changes were not associated with increased expression of Il-4 or Il-13 (Fig. 32e)
or with altered eosinophil or AAMac numbers (Fig. 32f) in iWAT.

3.5 Discussion
In this Chapter, we demonstrate that IL-33 is a critical regulator of beiging of
WAT. IL-33-induced beiging was mediated by ILC2s, and IL-33-elicited ILC2s
were sufficient to drive the formation of functional beige fat in wildtype mice. In
addition, IL-33 and ILC2s could elicit beiging in mice that lack an adaptive
immune system, eosinophils or IL-4Rα signaling.

This suggests that the IL-

33/ILC2 axis has the capacity to promote beiging of WAT independent of T cells
and the eosinophil/IL-4Rα/AAMac/norepinephrine pathway. Employing analyses
of obesity-associated genes, we identify that ILC2s produce the previously
unappreciated effector molecule MetEnk. Finally, we demonstrate that MetEnk
can drive beiging in vivo and upregulate Ucp1 expression levels in primary
adipocytes from iWAT.

Previous studies indicate that the immune system can have an important role in
the generation of beige adipose. Specifically, eosinophils are suggested to be
activated and produce IL-4 in iWAT of mice exposed to cold environmental
temperatures (Qiu et al., 2014). This leads to IL-4/IL-4Rα-dependent stimulation
of

AAMacs

in

iWAT

to

produce

norepinephrine

and

possibly

other

catecholamines that elicit beiging and increase the metabolic rate of mice (Qiu et
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al., 2014). Meteorin-like (Metrnl) is a hormone produced by adipose and muscle
tissue and elicits beiging in iWAT by inducing local eosinophil accumulation and
AAMac activation (Rao et al., 2014).

Mice that lack eosinophils (DblGata1

mutant mice) or IL-4/IL-13-dependent signaling (Il4/13−/− mice) have impaired
Ucp1 upregulation following cold exposure (Qiu et al., 2014), and administration
of exogenous Meteorin-like produces attenuated beiging in DblGata1 or STAT6deficient mice that have defective AAMacs (Rao et al., 2014). However, cold
exposure and exogenous Meteorin-like can elicit beiging in these strains albeit in
a less efficient manner (Qiu et al., 2014; Rao et al., 2014). This provokes the
hypothesis

that

there

are

other

pathways

beyond

the

eosinophil/IL-

4Rα/AAMac/norepinephrine pathway that can contribute to beiging in mice.
Consistent with this, we observe that IL-33 treatment or adoptive transfer of IL33-elicited ILC2s form E-WAT is sufficient to drive beiging of iWAT in wildtype
mice as well as DblGata1 mice that lack eosinophils and IL-4Rα-deficient mice
that have dysregulated AAMacs.

Although it is likely that eosinophils and

AAMacs contribute to optimal beiging in some physiologic contexts such as cold
exposure (Qiu et al., 2014; Rao et al., 2014), the data presented in this Chapter
indicate that the IL-33/ILC2 axis can elicit beiging independently of these
pathways.

Supporting this, we identified that ILC2s produce the pentapeptide MetEnk and
reveal a previously unappreciated role for MetEnk in stimulation of beiging in
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vivo. Delivery of MetEnk peptides to mice elicited beiging of WAT without
affecting the numbers of eosinophils or AAMacs, suggesting that the IL33/ILC2/MetEnk pathway might elicit beiging independently of these cell types.
Consistent with this, treatment of primary adipocytes from iWAT with MetEnk
increased Ucp1 expression levels, indicating a direct stimulatory effect of MetEnk
on adipocytes. Recent studies suggest that there are multiple developmental
pathways to beige adipocytes, including differentiation form a bipotent
white/beige pre-adipocyte (Lee et al., 2012) and transdifferentiation of mature
white adipocytes to beige adipocytes (Barbatelli et al., 2010; Rosenwald et al.,
2013). Future studies will be required to investigate the mechanisms through
which MetEnk elicits beiging.

MetEnk has previously been to be produced by neurons to limit anxiety, pain and
aggression levels in mice (Konig et al., 1996) and to promote conditioned
learning and addiction in mice (Tseng et al., 2013). In addition to these neuronal
processes, MetEnk was shown to act directly on adipocytes to stimulate lipolysis
(Nencini and Paroli, 1981), indicating that this neuronal-associated peptide also
has metabolic effects. Importantly, lipolysis is critical for the maintenance of
beige adipocyte function (Dong et al., 2013; Mottillo et al., 2012; Nguyen et al.,
2011). Further, UCP1 functions as a long-chain fatty acid-proton symporter and
employs long-chain fatty acids for efficient uncoupling (Fedorenko et al., 2012).
Thus, while MetEnk upregulates Ucp1 transcript levels in adipocytes, the lipolytic
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effects of MetEnk may also contribute to beiging and the regulation of beige
adipocyte function.

MetEnk peptides are derived from Proenkephalin A (PENK) via PCSK1dependent processing (Seidah, 2011; Seidah et al., 2013). Single nucleotide
polymorphisms in PCSK1 have been previously linked to the development of
obesity in humans (Benzinou et al., 2008; Creemers et al., 2012; Lloyd et al.,
2006), and this has been associated with PCSK1 effects on both food intake and
energy storage (Lloyd et al., 2006).

Obesity has also been associated with

decreased beige fat activation in humans (Carey et al., 2013; Saito et al., 2009),
and murine studies demonstrate that defective beige fat leads to increased
susceptibility to obesity (Cohen et al., 2014). The previous Chapter indicated
that decreased ILC2 responses in WAT are a conserved feature of obesity in
mice and humans and suggested the IL-33/ILC2 pathway may be dysregulated in
obese WAT. In light of these findings, the data in the present Chapter suggest
that PCSK1 mutations might affect weight gain through regulation of the
PENK/MetEnk/beiging pathway.

Collectively, the data in this Chapter provide the first demonstration that the IL33/ILC2 axis regulates metabolic homeostasis by eliciting beiging of WAT.
Production of enkephalin peptides is a previously unrecognized effector
mechanism employed by ILC2s to regulate metabolic homeostasis. From an
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evolutionary perspective, coupling ILC2-dependent innate immune effector
functions with the maintenance of systemic metabolic homeostasis could provide
a rapid, integrated multi-organ response that allows mammals to surmount
multiple environmental challenges including infection, nutrient stress or changes
in temperature.

Given that impaired UCP1 and beige adipocyte function is

associated with increased weight gain and obesity in mice (Cohen et al., 2014;
Feldmann et al., 2009) and that activity of brown/beige (Sharp et al., 2012; Wu et
al., 2012) adipose tissue is dysregulated in obese patients (Carey et al., 2013;
Saito et al., 2009), targeting the IL-33/ILC2/beiging pathway could represent a
new approach for treating obesity and obesity-associated diseases.
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3.6 Tables and Figures
Table 2. List of genes with single nucleotide polymorphisms associated
with human obesity
Human
gene
symbol
ADAMTS9
BCDIN3D
BDNF
CADM2
CNR1
CPEB4
CTNNBL1
DLK1
ENPP1
ETV5
FAIM2
FANCL
FTO
GHSR
GIPR
GNPDA2
GPRC5B
GRB14
HMGA1
HMGCR
HOXC13
ITPR2

Human gene name
A disintegrin-like and
metallopeptidase (reprolysin type)
with thrombospondin type 1 motif, 9
BCDIN3 domain containing
Brain-derived neurotrophic factor
Cell adhesion molecule 2
Cannabinoid type 1 receptor
Cytoplasmic polyadenylation element
binding protein 4
Catenin, beta like 1
Delta-like homologue 1
Ectonucleotide
pyrophasphatase/phosphodiesterase
1
Ets variant 5
Fas apoptotic inhibitory molecule 2
Fanconi anemia, complementation
group L
fat mass and obesity associated
Growth hormone receptor
secretogogue receptor
Gastric inhibitory polypeptide
receptor
Glucosamine-6-phosphate
deaminase 2
G protein-coupled receptor, family C,
group 5, member B
Growth factor receptor-bound protein
14
High mobility group AT-hook 1
3-hydroxy-3-methylglutaryl-CoA
reductase
Homeobox C13
Inositol 1,4,5-trisphosphate receptor,
type 2
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Murine
ortholog
gene
symbol

Inclusion
in
Microarray

Adamts9
Bcdin3d
Bdnf
Cadm2
Cnr1

Yes
Yes
Yes
Yes
Yes

Cpeb4
Ctnnbl1
Dlk1

Yes
Yes
Yes

Enpp1
Etv5
Faim2

Yes
Yes
Yes

Fancl
Fto

Yes
Yes

Ghsr

Yes

Gipr

Yes

Gnpda2

Yes

Gprc5b

Yes

Grb14
Hmga1

Yes
Yes

Hmgcr
Hoxc13

Yes
Yes

Itpr2

Yes

KCTD15
KLF7
LEP
LEPR
LMNA
LRP1B
LINGO2
(LRRN6C)
LY86
LYPLAL1
MAF
MAP2K5
MC4R
MSRA
MTCH2
MTIF3
MTMR9
NAMPT
NCR3
NEGR1
NFE2L3
NPC1
NPY2R
NRXN3
PCSK1
PIGC
POMC
PRKD1
PRL
PTBP2
PTER
RSPO3
SDCCAG8
SEC16B

Potassium channel tetramerization
domain containing 15
Kruppel-like factor 7
Leptin
Leptin receptor
Lamin A/C
Low density lipoprotein receptorrelated protein 1B
Leucine rich repeat and Ig domain
containing 2
Lymphocyte antigen 86
Lysophospholipase-like 1
v-maf avian musculoaponeurotic
fibrosarcoma oncogene homolog
Mitogen-activated protein kinase
kinase 5
Melanocortin 4 receptor
Methionine sulfoxide reductase A
Mitochondrial carrier 2
Mitochondrial translational initiation
factor 3
Myotubularin related protein 9
Nicotinamide
phosphoribosyltransferase
Natural cytotoxicity triggering
receptor 3
Neuronal growth regulator 1
Nuclear factor, erythroid 2-like 3
Niemann-Pick disease, type C1
Neuropeptide Y receptor Y2
Neurexin 3
Proprotein convertase subtilisin/kexin
type 1
Phosphatidylinositol glycan anchor
biosynthesis, class C
Proopiomelanocortin
Protein kinase D1
Prolactin
Polypyrimidine tract binding protein 2
Phosphotriesterase related
R-spondin 3
Serologically defined colon cancer
antigen 8
SEC16 Homolog B
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Kctd15
Klf7
Lep
Lepr
Lmna

Yes
Yes
Yes
Yes
Yes

Lrp1b

Yes

Lingo2
Ly86
Lyplal1

Yes
Yes
Yes

Maf

Yes

Map2k5
Mc4r
Msra
Mtch2

Yes
Yes
Yes
Yes

Mtif3
Mtmr9

Yes
Yes

Nampt

Yes

Ncr3
Negr1
Nfe2l3
Npc1
Npy2r
Nrxn3

No
Yes
Yes
Yes
Yes
Yes

Pcsk1

Yes

Pigc
Pomc
Prkd1
Prl
Ptbp2
Pter
Rspo3

Yes
Yes
Yes
Yes
Yes
Yes
Yes

Sdccag8
Sec16b

Yes
Yes

SH2B1
SLC39A8
SNRPN
SOCS1
SOCS3
STAB1
TBC1D1
TBX15
TFAP2B
TMEM160
TMEM18
TNNI3K
TUB
VEGFA
ZNF608
ZNRF3

SH2B adaptor protein 1
Solute carrier family 39 (zinc
transporter), member 8
Small nuclear ribonucleoprotein
polypeptide N
Suppressor of cytokine signaling 1
Suppressor of cytokine signaling 3
Stabilin 1
TBC1 (tre-2/USP6, BUB2, cdc16)
domain family, member 1
T-box 15
Transcription factor AP-2 beta
(activating enhancer binding protein 2
beta)
Transmembrane protein 160
Transmembrane protein 18
TNNI3 interacting kinase
Tubby bipartite transcription factor
Vascular endothelial growth factor A
Zinc finger protein 608
Zinc and ring finger 3
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Sh2b1

Yes

Slc39a8

Yes

Snrpn
Socs1
Socs3
Stab1

Yes
Yes
Yes
Yes

Tbc1d1
Tbx15

Yes
Yes

Tfap2b
Tmem160
Tmem18
Tnni3k
Tub
Vegfa
Zfp608
Znrf3

No
Yes
Yes
Yes
Yes
Yes
Yes
Yes

Figure 19.
Administration of recombinant murine IL-33 is
associated with increased beiging of white adipose tissue (WAT).
Wildtype C57BL/6 mice were treated with PBS or recombinant murine
IL-33 (12.5 µg/kg/day) by intraperitoneal injection for 7 days. (a)
Epididymal (E)-WAT and inguinal (i)WAT Uncoupling protein 1 (UCP1)
immunohistochemistry. Scale bars, 100 µm. (b) Ucp1 transcript levels
in E-WAT and iWAT. Student’s t-test, *P<0.05, ***P<0.001.
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Figure 20. Brown adipose tissue (BAT) contains Lin− CD25+ IL-33R+
ILC2s that expand in response to IL-33 in association with decreased
Ucp1 expression. C57BL/6 male mice (10 weeks old) were treated with
PBS (n=8) or IL-33 (12.5 µg/kg, n=8) daily by intraperitoneal injection for 7
days. (a) Representative plots and frequencies of Lin− CD25+ IL-33R+
ILC2s in interscapular BAT. Gated on live CD45+ Lin− cells. (b) Numbers of
ILC2s per gram of BAT. (c) Ucp1 expression in BAT by real-time PCR. (d)
Uncoupling protein 1 (UCP1) immunohistochemistry of BAT at 10X
magnification. Scale bars, 100 µm. (e) 40X magnification of panel d. Scale
bars, 100 µm. Student’s t-test, *<0.05, ***P<0.001.
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Figure 21. IL-33-deficient mice exhibit defective beiging of white
adipose tissue (WAT). (a-c) Il33+/+ (n=6) or Il33−/− (n=5) mice were fed a
low fat diet (10% kcal fat) for 12 weeks starting at age 7 weeks. Uncoupling
protein 1 (UCP1) immunohistochemistry (IHC) in inguinal (i)WAT from (a)
Il33+/+ or (b) Il33−/− mice. Scale bars, 100 µm. (c) Ucp1 transcript levels in
iWAT.
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Figure 22. Adoptive transfer of IL-33-elicited ILC2s is sufficient to
drive beiging. (a) Experimental design for panels b-f. Live CD45+ Lin−
CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of CD45.1+ mice
treated with 12.5 µg/kg recombinant murine (rm)IL-33 daily for 7 days by
intraperitoneal injection. ILC2s (1 x 105 total) were transferred to
CD45.2+ recipient mice daily for 4 days by subcutaneous injection near
inguinal (i)WAT (5 x 104 ILC2s, split evenly bilaterally) and
intraperitoneal injection (5 x 104 ILC2s). Tissues were harvested on day
5 for analyses (PBS, n=8; ILC2, n=8 except panel f). (b) Representative
plots identifying donor and recipient ILC2s in iWAT. Plots pre-gated on
live CD45+ Lin− CD25+ IL33R+ cells. Lineage cocktail: CD3, CD5, CD19,
NK1.1, CD11c, CD11b and FcεRIα. (c) Total numbers of ILC2s per
gram iWAT.
(d) iWAT Uncoupling protein 1 (UCP1)
immunohistochemistry, bar 100 µm. (e) Ucp1 expression in iWAT. (f)
iWAT oxygen consumption (PBS, n=14; ILC2, n=15).
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Figure 23. IL-33-elicited ILC2s derived from white adipose tissue
(WAT) selectively accumulate in recipient WAT. Live CD45+ Lin−
CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of CD45.1+ mice
treated with 12.5 µg/kg recombinant murine (rm)IL-33 daily for 7 days
by intraperitoneal injection. ILC2s (1 x 105 total) were transferred to
CD45.2+ recipient mice daily for 4 days by subcutaneous injection near
iWAT (5 x 104 ILC2s, split evenly bilaterally) and intraperitoneal
injection (5 x 104 ILC2s). Tissues were harvested on day 5 for
analyses. (b) Donor and recipient ILC2s in E-WAT, brown adipose
tissue (BAT), mesenteric lymph nodes (mLN) and lung. iWAT ILC2
plots from this experiment are shown in the previous figure. Pre-gated
on Live CD45+ Lin− CD25+ IL-33R+ ILC2s. Donor ILC2s are defined as
CD45.1+ CD45.2−, whereas recipient ILC2s are defined as CD45.1−
CD45.2+. Representative plots shown. Frequencies represent percent
of ILC2s that are recipient or donor cells. Student’s t-test, ***P<0.001.
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Figure 24. IL-33-elicited ILC2s can elicit beiging independently
of the adaptive immune system. Live CD45+ Lin− CD25+ IL-33R+
ILC2s were sort-purified from E-WAT of C57BL/6 mice treated with
rmIL-33 (12.5 µg/kg) daily for 7 days by intraperitoneal injection.
ILC2s (1 x 105 total) were transferred to Rag1−/− recipient mice on a
C57BL/6 background daily for 4 days by subcutaneous injection (n=8
mice per group). (a) Representative plots identifying donor and
recipient ILC2s in iWAT. Plots pre-gated on live CD45+ Lin− CD25+
IL33R+ cells. Lineage cocktail: CD3, CD5, CD19, NK1.1, CD11c,
CD11b and FcεRIα. (b) Total numbers of ILC2s per gram iWAT. (c)
iWAT Uncoupling protein 1 (UCP1) immunohistochemistry, bar 100
µm. (d) iWAT Ucp1 expression levels. Student’s t-test, *P<0.05,
**P<0.01.
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Figure 25. ILC2s from E-WAT accumulate in white adipose tissue
(WAT) of recipient mice and expand in response to IL-33 to
promote beiging. Experimental design for panels b-e. Sort-purified
CD45.1+ ILC2s (105) from E-WAT of IL-33-treated mice (12.5
µg/kg/day for 7 days by intraperitoneal [i.p.] injection) were transferred
into Rag2−/− γc−/− recipients by a single i.p. injection. ILC2-sufficient
Rag2−/− mice, ILC2-deficient Rag2−/− γc−/− mice and ILC2-reconstituted
Rag2−/− γc−/− mice were treated with PBS or rmIL-33 (12.5 µg/kg) by
intraperitoneal injection daily for 7 days (n=4 mice per group). (b)
Representative plots of live CD45.1+ Lin− CD25+ IL33R+ ILC2s in EWAT. Blue, recipient cells. Red, donor cells. Lineage cocktail includes
CD3, CD5, CD19, NK1.1, CD11c, CD11b and FcεRIα. (c) ILC2
numbers per gram of E-WAT. (d) Ucp1 expression in E-WAT. (e)
iWAT UCP1 immunohistochemistry, bar 100 µm. ANOVA with Tukey
post-hoc test, ***P<0.001.
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Figure 26. IL-33 treatment can elicit beiging independently of
eosinophils and IL-4Rα signaling. 	
  Wildtype (Balb/c), DblGata1 mice that
lack eosinophils or Il4ra−/− mice that have dysregulated alternatively
activated macrophages (AAMacs) (both mutant strains on a Balb/c
background) were treated with PBS or recombinant murine (rm)IL-33 (12.5
µg/kg) daily by intraperitoneal injection for 7 days. (a) ILC2 numbers/gram
iWAT and (b) iWAT UCP1 immunohistochemistry (IHC) in Balb/c mice. (c)
iWAT ILC2 numbers per gram of adipose and (d) iWAT UCP1 IHC in
DblGata1 mice. (e) ILC2 numbers/gram iWAT and (f) iWAT UCP1 IHC in
Il4ra−/− mice. Student’s t-test, *P<0.05. There were 3-6 mice per group
from 2 independent experiments. Scale bars, 100 µm.
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Figure 27.
IL-33-elicited ILC2s can promote beiging
independently of eosinophils and IL-4Rα signaling. Live CD45+
Lin− CD25+ IL-33R+ ILC2s were sort-purified from E-WAT of Balb/c
mice treated with rmIL-33 (12.5 µg/kg) daily for 5-7 days by
intraperitoneal injection. ILC2s (1 x 105 total) were transferred to the
indicated recipient mice daily for 4 days by subcutaneous injection. (a)
iWAT ILC2 numbers per gram of adipose and (b) iWAT Uncoupling
protein 1 (UCP1) immunohistochemistry (IHC) in DblGata1 recipients.
(c) iWAT ILC2 numbers per gram of adipose and (d) iWAT UCP1 IHC
in Il4ra−/− recipients. Student’s t-test, *P<0.05. Data are from n=3-6
mice per group pooled over 2-3 independent experiments. Scale bars,
100 µm.
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Figure 28.
Chronic exposure to severe cold environmental
temperatures is not associated with accumulation of ILC2s in inguinal
white adipose tissue (iWAT) or brown adipose tissue (BAT). C57BL/6
mice were single-housed at room temperature (n=7) or 4 °C (n=8) for 72
hours. (a) Uncoupling protein 1 (Ucp1) mRNA levels in iWAT and BAT. (b)
ILC2 numbers per gram of adipose tissue in iWAT and BAT. (c) Interleukin
33 (Il33) mRNA levels in iWAT and BAT. Student’s t-test, **P<0.01,
***P<0.001.
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Figure 29. ILC2s produce the obesity-associated gene PCSK1 and the
PCSK1 target methionine-enkephalin. (a) Gene expression enrichment
analyses of 69 obesity-associated genes in ILC2s (x-axis) versus ILC3s (yaxis). Genes significantly enriched in one cell type but not the other are red.
(b) Differential expression of PCSK1 target genes in ILC2s vs ILC3s. (c)
Intracellular staining of MetEnk (black line) or rabbit IgG isotype control
(shaded histogram) in ILC2s sort-purified from E-WAT and re-stimulated in
vitro with IL-2 and IL-7 (10 ng/mL) for 4 days. (d) MetEnk mean
fluorescence intensity (MFI) in sort-purified E-WAT ILC2s re-stimulated in
vitro with IL-2 and IL-7 (10 ng/mL) with or without IL-33 (30 ng/mL) for 4
days. Isotype control MFI for each group was subtracted before calculating
relative expression. Shown are averages from 4 independent experiments,
each representing pooled cells from n=3-5 mice and measured in duplicate
or triplicate.
117

Figure 30. Interleukin 33 (Il33) and Proenkephalin A (Penk)
expression levels are tissue specific. (a) Il33 and Penk mRNA levels
in inguinal white adipose tissue (iWAT) vs brown adipose tissue (BAT),
n=8 mice, paired samples. (b) Il33 and Penk mRNA expression levels
are correlated in iWAT but not BAT. Linear regression, n=16 mice,
naïve C57BL/6 mice. (c) Ogfr and Oprd1 mRNA levels in inguinal white
adipose tissue (iWAT) vs brown adipose tissue (BAT), n=8 mice, paired
samples. For panels a and c, Paired Student’s t-test, *P<0.01,
***P<0.001. For panel b, Pearson linear regression.
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Figure 31. Methionine-enkephalin (MetEnk) treatment upregulates
Uncoupling protein 1 (Ucp1) expression in primary adipocytes from
inguinal white adipose tissue (iWAT). Adherent stromal vascular
fraction (SVF) cells from (a) iWAT or (b) BAT of 4-week-old C57BL/6
mice were differentiated into adipocytes for 2 days, treated with PBS or
50 µM MetEnk from days 2-8 and harvested on day 8 (iWAT: n=7 PBS,
n=8 MetEnk; BAT: n=6 PBS, n=6 MetEnk from 2-3 independent
experiments). Student’s t-test, **P<0.01.
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Figure 32. Methionine-enkephalin (MetEnk) treatment can elicit
beiging in vivo. Wildtype mice were treated with PBS (n=7) or MetEnk
(n=9) by subcutaneous injection (10 mg/kg/day) for 5 days. (a)
Uncoupling protein 1 (UCP1) immunohistochemistry (IHC) in inguinal
white adipose tissue (iWAT). Scale bars, 100 µm. (b) iWAT Ucp1
expression, (c) iWAT oxygen consumption, (d) iWAT relative mass, (e)
iWAT Il4 and Il13 expression and (f) numbers of eosinophils (Eos, live
CD45+ SiglecF+ SSChi) and alternatively activated macrophages
(AAMacs, live CD45+ SiglecF- F4/80+ CD206+) per gram of iWAT.
Student’s t-test, *P<0.05, **P<0.01.
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CHAPTER 4: Summary, Discussion and Future Directions

4.1 Characterization of Group 2 innate lymphoid cell responses in
white adipose tissue
Group 2 innate lymphoid cells (ILC2s) are a recently described immune cell type
(Moro et al., 2009; Price et al., 2010; Neill et al. 2010) that respond to epithelialderived cytokines that include IL-33, IL-25 and thymic stromal lymphopoietin
(TSLP) to initiate type 2 immune responses that promote host protective
immunity against helminth pathogens or pathologic allergic inflammation (Kim,
2014; Monticelli et al., 2012; Sonnenberg et al., 2013; Spits et al., 2013; Spits
and Cupedo, 2012). ILC2s initiate type 2 immune responses in multiple tissues
by producing IL-5 and IL-13 that act to promote eosinophil and AAMac
responses, respectively (Molofsky et al., 2013; Nussbaum et al., 2013), although
these cells can also promote adaptive T helper type 2 (Th2) and B cell responses
in some contexts (Halim et al., 2014; Mirchandani et al., 2014; Moro et al., 2010;
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Oliphant et al., 2014).

Production of type 2 cytokines by ILC2s is critically

regulated by the transcription factor GATA-3 (Furusawa et al., 2013; Mjosberg et
al., 2012), a transcription factor that also controls ILC2 development (Monticelli et
al., 2012; Sonnenberg et al., 2013; Spits and Cupedo, 2012). Although ILC2
responses are associated with immune responses at barrier surfaces such as the
gut and lung, ILC2s were also recently demonstrated to be present in WAT,
where these cells constitutively produce IL-5 and IL-13 to sustain eosinophils and
AAMacs (Molofsky et al., 2013). ILC2-mediated activation of the eosinophil/IL4/AAMac pathway in WAT has been implicated in limiting obesity (Hams et al.,
2013; Molofsky et al., 2013; Wu et al., 2011). In addition, IL-33 has been shown
to have protective effects on inflammatory responses in WAT and for limiting
obesity (Miller et al., 2010). Based on these findings, the goal of this thesis was
to investigate ILC2 responses in WAT in the setting of murine and human obesity
and the mechanisms through which the IL-33/ILC2 pathway influences metabolic
homeostasis.

The results presented in this thesis identify IL-33R+ GATA-3+ ILC2s in human
and murine WAT and reveal a previously unappreciated link between IL-33dependent ILC2 responses and beiging of WAT. In Chapter 2, decreased WAT
ILC2 populations were found to be a conserved feature of obesity in humans and
mice. In mice, IL-33 was critical for promoting ILC2 responses in WAT and
limiting the development of obesity in mice, and treatment of mice with IL-33 was
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associated with increased metabolic rate.

In Chapter 3, IL-33 is shown to

promote beiging of WAT in a process mediated by ILC2s. IL-33-elicited ILC2s
could drive beiging independently of the adaptive immune system and the
eosinophil/IL-4Rα/AAMac pathway.

It was found that ILC2s produced

methionine-enkephalin (MetEnk) peptides, which were sufficient to drive beiging
in vivo and in vitro, indicating that the IL-33/ILC2 axis elicits beiging via
production of MetEnk peptides.

Previous studies have implicated ILC2s in limiting obesity in mice and have
indicated that ILC2s in WAT can expand in response to exogenous IL-33 (Hams
et al., 2013; Molofsky et al., 2013). However, the relevance of ILC2 responses in
human obesity remained unknown.

In addition, the endogenous factors that

control ILC2 responses in WAT and the mechanisms through which ILC2s
regulate metabolic homeostasis remain poorly understood. In Chapter 2, using
human subcutaneous WAT and murine epididymal (E)-WAT, we identified
Lineage (Lin)− CD25+ CD127+ ILCs that were uniformly positive for the IL-33R+
GATA-3+ ILC2s in both species. WAT ILC2 populations were decreased in both
murine and human obesity, suggesting that there may be a conserved
immunologic response in human and murine obesity that suppresses ILC2s.

123

The mechanisms of this decrease in ILC2s is not clear, however one possibility is
that ILC2s become resistant to the effects of IL-33 (i.e., hypo-responsiveness to
IL-33). Consistent with this hypothesis are recent studies indicating that IL-33
production is elevated in WAT of obese mice and humans (Zeyda et al., 2013),
which would be expected to result in increased ILC2 responses rather than the
observed decrease in ILC2s. Supporting this possibility are data in Chapter 2
indicating that endogenous IL-33 is necessary to sustain ILC2 responses in
WAT. Therefore, loss of IL-33-dependent signaling may contribute to decreased
ILC2 responses in obesity.

Another possible explanation for why ILC2s are

decreased in WAT may be related to decreases in other immune cell populations
in WAT that produce factors that stimulate ILC2s. For example, iNKT cells in
WAT are decreased in obesity and produce substantial amounts of IL-4 (Lynch et
al., 2014; Lynch et al., 2012), a factor that stimulates ILC2 proliferation and
effector cytokine production in the skin and lung (Kim et al., 2014; Motomura et
al., 2014). Direct associations between iNKT and ILC2 responses have not been
investigated. In addition, alternative mechanisms that might decrease ILC2s in
WAT are potential direct effects of fatty acids on ILC2s, or inflammatory signals
from other immune cell populations that suppress ILC2 responses.

Future

studies will be required to understand the mechanisms associated the decreased
ILC2 response in WAT in the context of obesity.
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IL-33 was previously shown to be an important regulator of adiposity and
inflammation in obese WAT (Miller et al., 2010), and exogenous IL-33 has been
shown to elicit ILC2 responses in WAT (Molofsky et al., 2013). The studies in
Chapter 2 support and extend these prior observations by indicating that
endogenous IL-33 is necessary to sustain ILC2s and to limit the development of
obesity. Recent studies showed that antibody-mediated depletion of ILC2s is
associated with increased weight gain and more severe insulin resistance in mice
fed a high fat diet (Hams et al., 2013), and transferring IL-25-elicted ILC2s is
sufficient to promote weight loss in diet-induced obese mice (Hams et al., 2013).
This suggests that ILC2s negatively regulate the development of obesity,
although the mechanisms of this remain poorly understood.

The studies in

Chapter 2 indicate that administration of exogenous IL-33 promoted ILC2
responses in WAT and decreased adiposity in association with increased energy
expenditure. This finding is consistent with earlier studies indicating that the
eosinophil/IL-4Rα/AAMac pathway can regulate caloric expenditure of mice
(Molofsky et al., 2013; Qiu et al., 2014; Rao et al., 2014; Wu et al., 2011).
Therefore, it is likely that ILC2s regulate metabolic homeostasis by eliciting the
eosinophil/IL-4Rα/AAMac pathway in WAT.

4.2 IL-33 and ILC2s promote beiging of white adipose tissue
Previous studies have indicated that the eosinophil/IL-4Rα/AAMac pathway
regulates energy expenditure by eliciting beiging of WAT (Liu et al., 2014; Qiu et
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al., 2014; Rao et al., 2014), a process in which UCP1-expressing beige
adipocytes emerge within WAT (Bartelt and Heeren, 2014; Harms and Seale,
2013; Rosen and Spiegelman, 2014; Wu et al., 2013). Eosinophils are recruited
to WAT in the setting of chronic exposure to severe cold environmental
temperatures (4°C), and these cells produce IL-4 to elicit AAMac production of
norepinephrine (Qiu et al., 2014; Rao et al., 2014). Although ILC2s are known to
be upstream mediators of eosinophil and AAMac responses in WAT (Molofsky et
al., 2013), whether ILC2s can contribute to beiging was unknown.

Data in

Chapter 3, indicate that IL-33 treatment and adoptive transfer of IL-33-elicited
ILC2s derived from WAT are sufficient to promote beiging.

Surprisingly,

however, the IL-33/ILC2 pathway could elicit beiging independently of
eosinophils and IL-4Rα.

Gene expression enrichment analyses of obesity-

associated genes in ILC2s indicated that ILC2s express PCSK1, a gene
previously linked to human and murine obesity by regulating both food intake and
caloric expenditure (Benzinou et al., 2008; Lloyd et al., 2006) by processing
various pro-hormones into their active forms (Seidah, 2011; Seidah et al., 2013).
We found that ILC2s produce the PCSK1 target gene Proenkephalin A and its
active form methionine-enkephalin, and this peptide could upregulate Ucp1
expression in adipocytes in vitro and elicit beiging in vivo.

Collectively, these findings suggest that ILC2s can elicit beiging via multiple
mechanisms (Fig. 33). First, ILC2s likely induce the eosinophil/IL-4Rα/AAMac
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pathway to promote beiging via production of norepinephrine (NE). In addition
ILC2s can produce MetEnk peptides that can directly stimulate beiging. It is not
yet clear whether NE and MetEnk elicit the same beige adipocyte subset.
However, we propose that NE and MetEnk cooperatively support optimal beiging
to regulate metabolic homeostasis. Supporting this are prior studies suggesting
that NE and MetEnk signaling pathways might interact to cooperatively stimulate
lipolysis in adipocytes (Nencini and Paroli, 1981), a process that is critical for
beige adipocyte responses and UCP1 function (Fedorenko et al., 2012; Harms
and Seale, 2013; Rosen and Spiegelman, 2014; Wu et al., 2013). Future studies
focused on MetEnk and NE interactions in adipocytes are warranted to better
understand that mechanisms by which ILC2s, eosinophils and AAMacs
contribute to the regulation of beiging and metabolic rate.

Another possibility is that ILC2-derived MetEnk and AAMac-derived NE elicit
distinct populations of beige adipocytes involved in the regulation of metabolic
homeostasis in different physiologic contexts. Supporting this, the eosinophil/IL4Rα/AAMac pathway is activated in WAT in the setting of chronic cold exposure
(Qiu et al., 2014; Rao et al., 2014), whereas data in Chapter 3 indicate that ILC2
numbers and Il33 expression were unchanged in iWAT following 3 days of
exposure to severe cold environmental temperatures. This suggests that the IL33/ILC2 pathway is not activated in the setting of cold exposure and that other
factors such as the adipokine/myokine meteorin-like or IL-4/IL-13-producing iNKT
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cells might elicit the eosinophil/AAMac-dependent beiging pathway (Lynch et al.,
2014; Lynch et al., 2012; Rao et al., 2014). Other metabolic functions of beige
adipocytes include limiting weight gain and promoting glucose homeostasis
(Cohen et al., 2014). As the IL-33/ILC2 axis appears to be dysregulated in the
setting

of

obesity

and

to

limit

weight

gain

(Chapter

2),

the

IL-

33/ILC2/MetEnk/beiging pathway might be associated with regulation of weight
gain or maintenance of glucose homeostasis. Additional studies will be required
to dissect the physiologic functions of ILC2s and MetEnk in the regulation of
beiging.

4.3 Concluding Remarks
Previous studies have implicated various type 2 immune cells in the regulation of
weight gain (see Chapter 1), and emerging work indicates that eosinophils and
AAMacs can promote beiging of WAT through AAMac-derived norepinephrine to
regulate energy expenditure (Liu et al., 2014; Qiu et al., 2014; Rao et al., 2014).
ILC2s produce effector cytokines that elicit type 2 immune responses (Kim, 2014;
Monticelli et al., 2012; Spits and Cupedo, 2012) and stimulate eosinophils and
AAMacs through production of IL-5 and IL-13 (Molofsky et al., 2013). Although
ILC2s have been implicated in limiting weight gain by regulating the
eosinophil/IL-4/AAMac pathway (Hams et al., 2013; Molofsky et al., 2013; Wu et
al., 2011), the relevance of ILC2 responses in human obesity and the
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mechanisms through which ILC2s regulate metabolic homeostasis have
remained poorly understood.

Collectively, the data presented in this thesis provide the first demonstration that
dysregulated ILC2 responses in WAT are a conserved feature of obesity in
humans and mice and that the IL-33-ILC2 axis regulates metabolic homeostasis
by eliciting beiging of white adipose tissue.

The expression of enkephalin

peptides within ILC2s indicates a previously unrecognized effector mechanism
employed by ILC2s to regulate metabolic homeostasis. From an evolutionary
perspective, coupling ILC2-dependent innate immune effector functions with the
maintenance of systemic metabolic homeostasis through beiging of WAT could
provide a rapid and integrated multi-organ response that allows mammals to
surmount multiple environmental challenges including infection, nutrient stress or
changes in temperature.

Given that impaired beige adipocyte function is

associated with increased weight gain and obesity in mice (Cohen et al., 2014;
Feldmann et al., 2009) and that activity of brown/beige (Sharp et al., 2012; Wu et
al., 2012) adipose tissue is dysregulated in obese patients (Carey et al., 2013;
Saito et al., 2009), targeting the IL-33-ILC2-beiging pathway could represent a
new approach for the treatment of obesity and obesity-associated disorders such
as type 2 diabetes and atherosclerosis.
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4.4 Figures

Figure 33. Summary model linking the IL-33/ILC2/MetEnk pathway
to the regulation of beiging and obesity. Interleukin (IL)-33 acts on
group 2 innate lymphoid cells (ILC2s) to upregulate production of the
effector molecules IL-5, IL-13 and enkephalin peptides. ILC2-derived IL5 promotes eosinophil homeostasis in WAT, and eosinophils in turn
produce IL-4 to sustain alternatively activated macrophages (AAMacs) in
WAT. ILC2-derived IL-13 can also promote AAMac responses. In the
setting of chronic exposure to a cold environment, eosinophil-derived IL4 stimulates AAMacs to produce catecholamines such as
norepinephrine, which acts directly on beige adipocytes to upregulate
uncoupling protein 1 (UCP1) expression and promote . Although it
remains unknown whether ILC2-derived IL-5 and IL-13 contribute to cold
stress-induced beiging, ILC2-derived enkephalin peptides can act
directly on beige adipocytes to upregulate UCP1. This results in
increased energy expenditure and decreased adiposity that may
counteract weight gain. In the setting of obesity, IL-33 expression in
WAT is increased, however WAT ILC2s are paradoxically decreased in
both mice and humans, suggesting that the IL-33/ILC2 axis is
dysregulated in obesity. This may impede the ability of ILC2s to
contribute to the function of beige fat, resulting in a vicious cycle that
promotes weight gain.
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